<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Heart J</journal-id><journal-id journal-id-type="iso-abbrev">Eur. Heart J</journal-id><journal-id journal-id-type="publisher-id">eurheartj</journal-id><journal-id journal-id-type="hwp">ehj</journal-id><journal-title-group><journal-title>European Heart Journal</journal-title></journal-title-group><issn pub-type="ppub">0195-668X</issn><issn pub-type="epub">1522-9645</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26374852</article-id><article-id pub-id-type="pmc">5841219</article-id><article-id pub-id-type="doi">10.1093/eurheartj/ehv422</article-id><article-id pub-id-type="publisher-id">ehv422</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research</subject><subj-group subj-group-type="category-toc-heading"><subject>Arrhythmia/Electrophysiology</subject></subj-group></subj-group><subj-group subj-group-type="category-oup-series"><subject>Editor's Choice</subject></subj-group></article-categories><title-group><article-title>Comparison of right ventricular septal pacing and right ventricular apical pacing in patients receiving cardiac resynchronization therapy defibrillators: the SEPTAL CRT Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Leclercq</surname><given-names>Christophe</given-names></name><author-comment content-type="other"><title>&#x02020;</title><p>These authors contributed equally.</p></author-comment><xref ref-type="aff" rid="af1">1</xref><xref ref-type="aff" rid="af2">2</xref><xref ref-type="aff" rid="af3">3</xref><xref ref-type="corresp" rid="cor1">*</xref><!--<email>christophe.leclercq@chu-rennes.fr</email>--></contrib><contrib contrib-type="author"><name><surname>Sadoul</surname><given-names>Nicolas</given-names></name><author-comment content-type="other"><title>&#x02020;</title><p>These authors contributed equally.</p></author-comment><xref ref-type="aff" rid="af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Mont</surname><given-names>Lluis</given-names></name><xref ref-type="aff" rid="af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Defaye</surname><given-names>Pascal</given-names></name><xref ref-type="aff" rid="af6">6</xref></contrib><contrib contrib-type="author"><name><surname>Osca</surname><given-names>Joaquim</given-names></name><xref ref-type="aff" rid="af7">7</xref></contrib><contrib contrib-type="author"><name><surname>Mouton</surname><given-names>Elisabeth</given-names></name><xref ref-type="aff" rid="af8">8</xref></contrib><contrib contrib-type="author"><name><surname>Isnard</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="af9">9</xref></contrib><contrib contrib-type="author"><name><surname>Habib</surname><given-names>Gilbert</given-names></name><xref ref-type="aff" rid="af10">10</xref></contrib><contrib contrib-type="author"><name><surname>Zamorano</surname><given-names>Jose</given-names></name><xref ref-type="aff" rid="af11">11</xref></contrib><contrib contrib-type="author"><name><surname>Derumeaux</surname><given-names>Genevieve</given-names></name><xref ref-type="aff" rid="af12">12</xref></contrib><contrib contrib-type="author"><name><surname>Fernandez-Lozano</surname><given-names>Ignacio</given-names></name><xref ref-type="aff" rid="af13">13</xref></contrib><on-behalf-of>the SEPTAL CRT Study investigators</on-behalf-of></contrib-group><aff id="af1">
<label>1</label>
<institution>Centre Hospitalier Universitaire</institution>, <addr-line>Rennes</addr-line>, <country>France</country></aff><aff id="af2">
<label>2</label>
<institution>Universit&#x000e9; Rennes 1</institution>, <addr-line>Rennes</addr-line>, <country>France</country></aff><aff id="af3">
<label>3</label>
<institution>Universit&#x000e9; Inserm U642</institution>, <addr-line>Rennes</addr-line>, <country>France</country></aff><aff id="af4">
<label>4</label>
<institution>Centre Hospitalier Universitaire</institution>, <addr-line>Nancy</addr-line>, <country>France</country></aff><aff id="af5">
<label>5</label>
<institution>Hospital Clinic Universitat de Barcelona</institution>, <addr-line>Catalonia</addr-line>, <country>Spain</country></aff><aff id="af6">
<label>6</label>
<institution>Centre Hospitalier Universitaire</institution>, <addr-line>Grenoble</addr-line>, <country>France</country></aff><aff id="af7">
<label>7</label>
<institution>Hospital La F&#x000e9;</institution>, <addr-line>Valencia</addr-line>, <country>Spain</country></aff><aff id="af8">
<label>8</label>
<institution>Boston Scientific SAS</institution>, <addr-line>Voisins le Bretonneux</addr-line>, <country>France</country></aff><aff id="af9">
<label>9</label>
<institution>Centre Hospitalier Universitaire la Piti&#x000e9;-Salp&#x000ea;tri&#x000e8;re</institution>, <addr-line>Paris</addr-line>, <country>France</country></aff><aff id="af10">
<label>10</label>
<institution>Centre Hospitalier Universitaire La Timone</institution>, <addr-line>Marseille</addr-line>, <country>France</country></aff><aff id="af11">
<label>11</label>
<institution>University Hospital Ram&#x000f3;n y Cajal</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country></aff><aff id="af12">
<label>12</label>
<institution>DHU A-TVB, H&#x000f4;pital Henri Mondor</institution>, <addr-line>Cr&#x000e9;teil</addr-line>, <country>France</country></aff><aff id="af13">
<label>13</label>
<institution>Hospital Puerta de Hierro</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country></aff><contrib-group><contrib contrib-type="author"><collab>on behalf of the SEPTAL CRT Study investigators</collab></contrib><contrib contrib-type="author"><name><surname>Dupuis</surname><given-names>Jean-Marc</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rouleau</surname><given-names>Fr&#x000e9;d&#x000e9;ric</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tassin</surname><given-names>Aude</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bordachar</surname><given-names>Pierre</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cl&#x000e9;menty</surname><given-names>Jacques</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lafitte</surname><given-names>Stephane</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ploux</surname><given-names>Sylvan</given-names></name></contrib><contrib contrib-type="author"><name><surname>Reant</surname><given-names>Patricia</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ritter</surname><given-names>Philippe</given-names></name></contrib><contrib contrib-type="author"><name><surname>Defaye</surname><given-names>Pascal</given-names></name></contrib><contrib contrib-type="author"><name><surname>Jacon</surname><given-names>Peggy</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mondesert</surname><given-names>Blandine</given-names></name></contrib><contrib contrib-type="author"><name><surname>Saunier</surname><given-names>Carole</given-names></name></contrib><contrib contrib-type="author"><name><surname>Vautrin</surname><given-names>Estelle</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kacet</surname><given-names>Salem</given-names></name></contrib><contrib contrib-type="author"><name><surname>Guedon-Moreau</surname><given-names>Laurence</given-names></name></contrib><contrib contrib-type="author"><name><surname>Klug</surname><given-names>Didier</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kouakam</surname><given-names>Claude</given-names></name></contrib><contrib contrib-type="author"><name><surname>Marechaux</surname><given-names>Sylvestre</given-names></name></contrib><contrib contrib-type="author"><name><surname>Marquie</surname><given-names>Christelle</given-names></name></contrib><contrib contrib-type="author"><name><surname>Polge</surname><given-names>Anne Sophie</given-names></name></contrib><contrib contrib-type="author"><name><surname>Richardson</surname><given-names>Marjorie</given-names></name></contrib><contrib contrib-type="author"><name><surname>Chevallier</surname><given-names>Philippe</given-names></name></contrib><contrib contrib-type="author"><name><surname>De Breyne</surname><given-names>Brigitte</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lotek</surname><given-names>Marcin M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Nonin</surname><given-names>Emilie</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pineau</surname><given-names>Julien</given-names></name></contrib><contrib contrib-type="author"><name><surname>Deharo</surname><given-names>Jean-Claude</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bastard</surname><given-names>Emilie</given-names></name></contrib><contrib contrib-type="author"><name><surname>Franceschi</surname><given-names>Fr&#x000e9;d&#x000e9;ric</given-names></name></contrib><contrib contrib-type="author"><name><surname>Habib</surname><given-names>Gilbert</given-names></name></contrib><contrib contrib-type="author"><name><surname>Jego</surname><given-names>Christophe</given-names></name></contrib><contrib contrib-type="author"><name><surname>Peyrouse</surname><given-names>Eric</given-names></name></contrib><contrib contrib-type="author"><name><surname>Prevot</surname><given-names>Sebastien</given-names></name></contrib><contrib contrib-type="author"><name><surname>Saint-Joseph</surname><given-names>H&#x000f4;pital</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bremondy</surname><given-names>Michel</given-names></name></contrib><contrib contrib-type="author"><name><surname>Faure</surname><given-names>Jacques</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ferracci</surname><given-names>Ange</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lefevre</surname><given-names>Jean</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pisapia</surname><given-names>Andre</given-names></name></contrib><contrib contrib-type="author"><name><surname>Davy</surname><given-names>Jean-Marc</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cransac</surname><given-names>Frederic</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cung</surname><given-names>Tien Tri</given-names></name></contrib><contrib contrib-type="author"><name><surname>Georger</surname><given-names>Frederic</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pasquie</surname><given-names>Jean-Luc</given-names></name></contrib><contrib contrib-type="author"><name><surname>Raczka</surname><given-names>Franck</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sportouch-Dukhan</surname><given-names>Catherine</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sadoul</surname><given-names>Nicolas</given-names></name></contrib><contrib contrib-type="author"><name><surname>Blangy</surname><given-names>Hugues</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bruntz</surname><given-names>Jean-Fran&#x000e7;ois</given-names></name></contrib><contrib contrib-type="author"><name><surname>Freysz</surname><given-names>Luc</given-names></name></contrib><contrib contrib-type="author"><name><surname>Groben</surname><given-names>Laurent</given-names></name></contrib><contrib contrib-type="author"><name><surname>Huttin</surname><given-names>Olivier</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bammert</surname><given-names>Antoine</given-names></name></contrib><contrib contrib-type="author"><name><surname>Burban</surname><given-names>Marc</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cebron</surname><given-names>Jean-Pierre</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gras</surname><given-names>Daniel</given-names></name></contrib><contrib contrib-type="author"><name><surname>Frank</surname><given-names>Robert</given-names></name></contrib><contrib contrib-type="author"><name><surname>Duthoit</surname><given-names>Guillaume</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hidden-Lucet</surname><given-names>Fran&#x000e7;oise</given-names></name></contrib><contrib contrib-type="author"><name><surname>Himbert</surname><given-names>Caroline</given-names></name></contrib><contrib contrib-type="author"><name><surname>Isnard</surname><given-names>Richard</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lacotte</surname><given-names>J&#x000e9;r&#x000f4;me</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pousset</surname><given-names>Fran&#x000e7;oise</given-names></name></contrib><contrib contrib-type="author"><name><surname>Zerah</surname><given-names>Thierry</given-names></name></contrib><contrib contrib-type="author"><name><surname>Leclercq</surname><given-names>Christophe</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bellouin</surname><given-names>Anna&#x000ef;k</given-names></name></contrib><contrib contrib-type="author"><name><surname>Crocq</surname><given-names>Christophe</given-names></name></contrib><contrib contrib-type="author"><name><surname>Deplace</surname><given-names>Christian</given-names></name></contrib><contrib contrib-type="author"><name><surname>Donal</surname><given-names>Erwan</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hamon</surname><given-names>C&#x000e9;cile</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mabo</surname><given-names>Philippe</given-names></name></contrib><contrib contrib-type="author"><name><surname>Romain</surname><given-names>Olivier</given-names></name></contrib><contrib contrib-type="author"><name><surname>Solnon</surname><given-names>Aude</given-names></name></contrib><contrib contrib-type="author"><name><surname>Frederic</surname><given-names>Anselme</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bauer</surname><given-names>Fabrice</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bernard</surname><given-names>Mathieu</given-names></name></contrib><contrib contrib-type="author"><name><surname>Godin</surname><given-names>Benedicte</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kurtz</surname><given-names>Baptiste</given-names></name></contrib><contrib contrib-type="author"><name><surname>Savoure</surname><given-names>Arnaud</given-names></name></contrib><contrib contrib-type="author"><name><surname>Copie</surname><given-names>Xavier</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lascault</surname><given-names>Gilles</given-names></name></contrib><contrib contrib-type="author"><name><surname>Paziaud</surname><given-names>Olivier</given-names></name></contrib><contrib contrib-type="author"><name><surname>Piot</surname><given-names>Olivier</given-names></name></contrib><contrib contrib-type="author"><name><surname>Touche</surname><given-names>Thierry</given-names></name></contrib><contrib contrib-type="author"><name><surname>Delay</surname><given-names>Toulouse Marc</given-names></name></contrib><contrib contrib-type="author"><name><surname>Chilon</surname><given-names>Talia</given-names></name></contrib><contrib contrib-type="author"><name><surname>Detis</surname><given-names>Nicolas</given-names></name></contrib><contrib contrib-type="author"><name><surname>Duparc</surname><given-names>Alexandre</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hebrard</surname><given-names>Aur&#x000e9;lien</given-names></name></contrib><contrib contrib-type="author"><name><surname>Massabuau</surname><given-names>Pierre</given-names></name></contrib><contrib contrib-type="author"><name><surname>Maury</surname><given-names>Philippe</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mondoly</surname><given-names>Pierre</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rumeau</surname><given-names>Philippe</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pasteur</surname><given-names>Clinique</given-names></name></contrib><contrib contrib-type="author"><name><surname>Boveda</surname><given-names>Serge</given-names></name></contrib><contrib contrib-type="author"><name><surname>Adrover</surname><given-names>Laurence</given-names></name></contrib><contrib contrib-type="author"><name><surname>Combes</surname><given-names>Nicolas</given-names></name></contrib><contrib contrib-type="author"><name><surname>Deplagne</surname><given-names>Antoine</given-names></name></contrib><contrib contrib-type="author"><name><surname>Marco-Baertich</surname><given-names>Isabelle</given-names></name></contrib><contrib contrib-type="author"><name><surname>Fondard</surname><given-names>Olivier</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mart&#x000ed;nez</surname><given-names>Juan Gabriel</given-names></name></contrib><contrib contrib-type="author"><name><surname>Iba&#x000f1;ez Criado</surname><given-names>Jos&#x000e9; Luis</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ortu&#x000f1;o</surname><given-names>Diego</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mont</surname><given-names>Lluis</given-names></name></contrib><contrib contrib-type="author"><name><surname>Berruezo</surname><given-names>Antonio</given-names></name></contrib><contrib contrib-type="author"><name><surname>Eduard</surname><given-names>Belu</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mart&#x000ed;n</surname><given-names>Ana</given-names></name></contrib><contrib contrib-type="author"><name><surname>Merschon</surname><given-names>Franco M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sitges</surname><given-names>Marta</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tolosana</surname><given-names>Jos&#x000e9; Mar&#x000ed;a</given-names></name></contrib><contrib contrib-type="author"><name><surname>Vidal</surname><given-names>B&#x000e1;rbara</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hebron</surname><given-names>H. Valle</given-names></name></contrib><contrib contrib-type="author"><name><surname>i Mitjans</surname><given-names>Angel Moya</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rodriguez</surname><given-names>Oscar Alcalde</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rodriguez Palomares</surname><given-names>Jos&#x000e9; Fernando</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rivas</surname><given-names>Nuria</given-names></name></contrib><contrib contrib-type="author"><name><surname>Teixid&#x000f3;</surname><given-names>Gisela</given-names></name></contrib><contrib contrib-type="author"><name><surname>de Hierro</surname><given-names>H. Puerta</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lozano</surname><given-names>Ignacio Fern&#x000e1;ndez</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ruiz Bautista</surname><given-names>Maria Lorena</given-names></name></contrib><contrib contrib-type="author"><name><surname>Castro</surname><given-names>Victor</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cavero</surname><given-names>Miguel Angel</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gutierrez</surname><given-names>Carlos</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ros</surname><given-names>Natalia</given-names></name></contrib><contrib contrib-type="author"><name><surname>de la Victoria</surname><given-names>H. Virgen</given-names></name></contrib><contrib contrib-type="author"><name><surname>Alzueta Rodriguez</surname><given-names>Francisco Javier</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cabrera</surname><given-names>Fernando</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cordero</surname><given-names>Alberto Barrera</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pe&#x000f1;a</surname><given-names>Jos&#x000e9; Luis</given-names></name></contrib><contrib contrib-type="author"><name><surname>de Valme Sevilla</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gonz&#x000e1;les</surname><given-names>Juan Lealdel Ojo</given-names></name></contrib><contrib contrib-type="author"><name><surname>Garcia Medina</surname><given-names>M&#x000aa; Dolores</given-names></name></contrib><contrib contrib-type="author"><name><surname>Jim&#x000e9;nez</surname><given-names>Ricardo Pav&#x000f3;n</given-names></name></contrib><contrib contrib-type="author"><name><surname>Villagomez</surname><given-names>David</given-names></name></contrib><contrib contrib-type="author"><name><surname>de la Salud Toledo</surname><given-names>H. Virgen</given-names></name></contrib><contrib contrib-type="author"><name><surname>Castellanos Martinez</surname><given-names>Eduardo</given-names></name></contrib><contrib contrib-type="author"><name><surname>Alcal&#x000e1;</surname><given-names>Juan</given-names></name></contrib><contrib contrib-type="author"><name><surname>Maicas</surname><given-names>Carolina</given-names></name></contrib><contrib contrib-type="author"><name><surname>Arias Palomares</surname><given-names>Miguel Angel</given-names></name></contrib><contrib contrib-type="author"><name><surname>Puchol</surname><given-names>Alberto</given-names></name></contrib><contrib contrib-type="author"><name><surname>Valencia</surname><given-names>H. La F&#x000e9;</given-names></name></contrib><contrib contrib-type="author"><name><surname>OscaAsensi</surname><given-names>Joaquim</given-names></name></contrib><contrib contrib-type="author"><name><surname>Carmona</surname><given-names>Anastasio Quesada</given-names></name></contrib><contrib contrib-type="author"><name><surname>De Carranza</surname><given-names>M&#x000aa; Jos&#x000e9; Sancho-Tello</given-names></name></contrib><contrib contrib-type="author"><name><surname>De Ros</surname><given-names>Jos&#x000e9; Olag&#x000fc;e</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pareja</surname><given-names>Enrique Castro</given-names></name></contrib><contrib contrib-type="author"><name><surname>P&#x000e9;rez</surname><given-names>Oscar Cano</given-names></name></contrib><contrib contrib-type="author"><name><surname>Saez</surname><given-names>Ana Osa</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hortega</surname><given-names>H. Rio</given-names></name></contrib><contrib contrib-type="author"><name><surname>Guilarte</surname><given-names>Benito Herreros</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mu&#x000f1;oz San Jose</surname><given-names>Juan Francisco</given-names></name></contrib><contrib contrib-type="author"><name><surname>P&#x000e9;rez Sanz</surname><given-names>Teresa Myriam</given-names></name></contrib><contrib contrib-type="author"><name><surname>Logeart</surname><given-names>Damien</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gil</surname><given-names>Maria Lopez</given-names></name></contrib><contrib contrib-type="author"><name><surname>Leclercq</surname><given-names>Christophe</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lozano</surname><given-names>Ignacio Fernandez</given-names></name></contrib><contrib contrib-type="author"><name><surname>de Hierro</surname><given-names>H. Puerta</given-names></name></contrib><contrib contrib-type="author"><name><surname>Derumeaux</surname><given-names>Genevieve</given-names></name></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>Corresponding author. Tel: +33 29 928 2525, Fax: +33 29 925 2510, Email: <email>christophe.leclercq@chu-rennes.fr</email></corresp><fn id="AN1" fn-type="con"><label>&#x02020;</label><p>These authors contributed equally.</p></fn></author-notes><pub-date pub-type="ppub"><day>01</day><month>2</month><year>2016</year></pub-date><pub-date pub-type="epub" iso-8601-date="2015-09-15"><day>15</day><month>9</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>15</day><month>9</month><year>2015</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>37</volume><issue>5</issue><issue-title>Focus Issue on Heart Failure</issue-title><fpage>473</fpage><lpage>483</lpage><history><date date-type="received"><day>24</day><month>12</month><year>2014</year></date><date date-type="rev-recd"><day>17</day><month>7</month><year>2015</year></date><date date-type="accepted"><day>10</day><month>8</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; The Author 2015. Published by Oxford University Press on behalf of the European Society of Cardiology.</copyright-statement><copyright-year>2015</copyright-year><license license-type="cc-by-nc" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ehv422.pdf"/><abstract><title>Abstract</title><sec><title>Aims</title><p>Cardiac resynchronization therapy (CRT) is a recommended treatment of heart failure (HF) patients with depressed left ventricular ejection fraction and wide QRS. The optimal right ventricular (RV) lead position being a matter of debate, we sought to examine whether RV septal (RVS) pacing was not inferior to RV apical (RVA) pacing on left ventricular reverse remodelling in patients receiving a CRT-defibrillator.</p></sec><sec><title>Methods and results</title><p>Patients (<italic>n</italic> = 263, age = 63.4 &#x000b1; 9.5 years) were randomly assigned in a 1:1 ratio to RVS (<italic>n</italic> = 131) vs. RVA (<italic>n</italic> = 132) pacing. Left ventricular end-systolic volume (LVESV) reduction between baseline and 6 months was not different between the two groups (&#x02212;25.3 &#x000b1; 39.4 mL in RVS group vs. &#x02212;29.3 &#x000b1; 44.5 mL in RVA group, <italic>P</italic> = 0.79). Right ventricular septal pacing was not non-inferior (primary endpoint) to RVA pacing with regard to LVESV reduction (average difference = &#x02212;4.06 mL; <italic>P</italic> = 0.006 with a &#x02212;20 mL non-inferiority margin). The percentage of &#x02018;echo-responders&#x02019; defined by LVESV reduction &#x0003e;15% between baseline and 6 months was similar in both groups (50%) with no difference in the time to first HF hospitalization or death (<italic>P</italic> = 0.532). Procedural or device-related serious adverse events occurred in 68 patients (RVS = 37) with no difference between the two groups (<italic>P</italic> = 0.401).</p></sec><sec><title>Conclusion</title><p>This study demonstrates that septal RV pacing in CRT is non-inferior to apical RV pacing for LV reverse remodelling at 6 months with no difference in the clinical outcome. No recommendation for optimal RV lead position can hence be drawn from this study.</p></sec><sec><title>ClinicalTrials.
gov number</title><p>NCT 00833352.</p></sec></abstract><kwd-group><kwd>Cardiac resynchronization therapy</kwd><kwd>Right ventricular lead position</kwd><kwd>Right ventricular defibrillation lead</kwd><kwd>Left ventricular end-systolic volume</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Cardiac resynchronization therapy (CRT) is a recommended therapeutic strategy in the treatment of patients with symptomatic heart failure (HF) and depressed left ventricular ejection fraction (LVEF) and wide QRS.<sup><xref rid="EHV422C1" ref-type="bibr">1</xref></sup> Cardiac resynchronization therapy is obtained by simultaneous or sequential pacing of the right and left ventricles. Despite such implantation is technically successful in &#x0003e;90% of patients;<sup><xref rid="EHV422C2" ref-type="bibr">2&#x02013;4</xref></sup> clinical improvement or left ventricular (LV) reverse remodelling is achieved in no more than 2/3 of the patients. Several reasons may explain such incomplete response: sub-optimal patients selection,<sup><xref rid="EHV422C1" ref-type="bibr">1</xref>,<xref rid="EHV422C4" ref-type="bibr">4&#x02013;8</xref></sup> inadequate LV lead position,<sup><xref rid="EHV422C9" ref-type="bibr">9&#x02013;12</xref></sup> and sub-optimal programming.<sup><xref rid="EHV422C13" ref-type="bibr">13</xref></sup></p><p>Whether the right ventricular (RV) lead position may improve the response to CRT is a matter of debate. Apical position is conventional, especially in patients receiving a CRT-defibrillator (CRT-D) but long-term RV apical pacing may adversely affect cardiac function in intracardiac cardioverter defibrillator (ICD) recipients.<sup><xref rid="EHV422C14" ref-type="bibr">14&#x02013;16</xref></sup> Alternative RV pacing sites, mainly RV septal, have been recently proposed in CRT recipients. No significant benefit of these alternative RV pacing sites was demonstrated with the limitations of either retrospective analysis of large prospective trials,<sup><xref rid="EHV422C11" ref-type="bibr">11</xref>,<xref rid="EHV422C12" ref-type="bibr">12</xref></sup> prospective non-randomized trials,<sup><xref rid="EHV422C10" ref-type="bibr">10</xref>,<xref rid="EHV422C17" ref-type="bibr">17&#x02013;21</xref></sup> or single-centre randomized study.<sup><xref rid="EHV422C22" ref-type="bibr">22</xref></sup> We hence conducted a prospective randomized European multicentre trial to examine the effects of the RV lead positions, i.e. apical or septal, on the LV reverse remodelling in patients receiving a CRT-D.</p></sec><sec id="s2"><title>Study design and objectives</title><p>SEPTAL CRT is a randomized, controlled, single-blind, multicentre trial, including two parallel patient groups receiving a CRT-D randomly assigned to implantation of the ICD lead at the RV mid-septum (RVS) or at the RV apex (RVA). This study was approved by the Ethics Committee of Rennes University Hospital, France. All patients signed written, informed consent prior enrolment in the study. The study complied with the Declaration of Helsinki.</p><p>The primary objective was to demonstrate that RVS pacing was not inferior to RVA pacing in terms of changes in the left ventricular end-systolic volume (LVESV) between baseline and 6 months.</p><p>The main secondary objectives were:
</p><list list-type="order"><list-item><p>to assess the percentage of &#x02018;echo-responders&#x02019; defined by a reduction in LVESV &#x0003e;15% at 6 months;</p></list-item><list-item><p>to assess the implant success rate of the ICD lead using pre-specified electrical criteria;</p></list-item><list-item><p>to compare the clinical outcome between the two groups using the 6 minutes' walk test (6 MWT) and the Milton Packer score;<sup><xref rid="EHV422C23" ref-type="bibr">23</xref></sup> and</p></list-item><list-item><p>to assess the total mortality and HF hospitalizations at 12 months.</p></list-item></list></sec><sec id="s3"><title>Patient selection</title><p>The patients included in this trial were &#x02265;18 years of age and had indications for CRT-D implantation according to the 2008 European Society of Cardiology (ESC) guidelines,<sup><xref rid="EHV422C24" ref-type="bibr">24</xref></sup> i.e. patients with a documented LVEF (assessed by the implanting centre) &#x02264;35% in the last 3 months, a New York Heart Association (NYHA) class III or ambulatory class IV stable for the last month prior enrolment receiving optimal medical therapy for at least 1 month, a QRS &#x02265;120 ms with a stable sinus rhythm. The inclusion criteria were modified after the release of the ESC updated Guidelines 2010<sup><xref rid="EHV422C25" ref-type="bibr">25</xref></sup> with extension of the inclusion to NYHA class II patients with a QRS &#x02265;150 ms.</p></sec><sec id="s4"><title>Implantable cardioverter-defibrillator lead implantation</title><p>All patients received an ENDOTAK RELIANCE<sup>&#x000ae;</sup> G (Guidant/Boston Scientific, Natick, MA, USA) active fixation, single- or dual-coil ICD lead, implanted in the RVS vs. the RVA. Leads assigned to the RVS were considered optimally implanted when they were oriented frontally and towards the left in a 40&#x02013;45&#x000b0; left anterior oblique fluoroscopic projection (<italic>Figure <xref ref-type="fig" rid="EHV422F1">1</xref>A</italic>). Leads assigned to the RVA group were advanced as far as possible towards the RV apex (<italic>Figure <xref ref-type="fig" rid="EHV422F1">1</xref>B</italic>).<sup><xref rid="EHV422C26" ref-type="bibr">26</xref></sup> After implantation, the location of RV leads was reviewed by two physicians, in a blinded manner.
</p><fig id="EHV422F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Right ventricular lead apical and septal locations.</p></caption><graphic xlink:href="ehv42201"/></fig><p>Lead implantation was considered successful when the four following electrical endpoints were obtained: (i) R wave amplitude &#x0003e;5 mV, (ii) RV capture threshold &#x0003c;1.5 V/0.5 ms, (iii) pacing lead impedance between 450 and 1800 &#x003a9; at a 5 V, all measured with a pacing system analyser, and (iv) a 10 J safety margin for defibrillation threshold. If all these criteria were not obtained, a second attempt in an adjacent assigned position was performed. In case of subsequent failure, the lead was repositioned at the alternative site.</p></sec><sec id="s5"><title>Left ventricular lead implant</title><p>Left ventricular lead was inserted in the coronary sinus. The lateral position was targeted first, then the posterolateral position, and finally the posterior position. In case of coronary sinus lead implant failure, an epicardial lead was surgically implanted (<italic>n</italic> = 6).</p></sec><sec id="s6"><title>Echocardiographic methods</title><p>In each centre, echocardiographic recordings were performed by cardiologists certified for this study. The main following parameters were assessed:
Right and left pre-ejection delays and interventricular mechanical delay.</p><list list-type="simple"><list-item><p>&#x02013;&#x02003;Left ventricular end-systolic and end-diastolic diameters (LVESD and LVEDD),</p></list-item><list-item><p>&#x02013;&#x02003;Left ventricular end-systolic volume and LVEDVs,</p></list-item><list-item><p>&#x02013;&#x02003;Left ventricular ejection fraction calculated by the Simpson method, and</p></list-item><list-item><p>&#x02013;&#x02003;Left ventricular filling time.</p></list-item></list><p>Left ventricular volumes were measured in the apical two and four chambers views and averaged. Left ventricular ejection fraction, left atrial area, and LV diameters were measured using standard methods. Echocardiograms were sent on digital storage media to an independent echocardiographic core laboratory (Genevieve Derumeaux, University Hospital, Cr&#x000e9;teil, France), where they were screened for quality. All measurements were made at baseline and in patients with echocardiograms available at 6 and 12 months. Core laboratory intra- and inter-observer variabilities of echocardiographic parameters measurements have been reported earlier and were, respectively, 12 and 16% for LVESV.<sup><xref rid="EHV422C27" ref-type="bibr">27</xref></sup></p></sec><sec id="s7"><title>Baseline data, follow-up, and data collection</title><p>Device interrogation was performed at pre-discharge, at 1, 6, and 12 months. Following tachycardia parameters were recommended for ICD programming: ventricular fibrillation (VF) zone &#x02265;220 b.p.m. and in case of a ventricular tachycardia (VT) zone, a minimum of six anti-tachycardia pacing attempts before shock delivery. Electrical lead characteristics as well as arrhythmic events were collected at each interrogation. AV delay optimization was performed before discharge using the iterative mitral flow method under echocardiography. New York Heart Association class was assessed at each follow-up by a physician blinded to the lead position. The 6 MWT and the Milton Packer test were performed at baseline, 6, and 12 months and assessed by a blinded observer.</p></sec><sec id="s8"><title>Statistical analysis</title><p>The study planned to include 240 patients to prove the non-inferiority of RVS pacing in terms of LVESV reduction at 6 months with a 90% power at 2.5% unilateral significance level, and a rate of 33% of non-available assessments at 6 months. The intention to treat (ITT) population included all randomized patients. Patients without at least one major deviation and with LVESV measurable at baseline represented the per protocol (PP) population.</p><p>The ITT population was analysed according to the randomized group while the PP population was analysed according to the implanted site. For both the ITT and PP populations, non-inferiority was analysed by examining the lower limit of the confidence interval of the difference in LVESV reduction between groups. If the lower limit was greater than the non-inferiority margin of &#x02212;20 mL, the null hypothesis was rejected and the septal group was considered non-inferior with regard to the apical group. Superiority analysis was conducted if non-inferiority was achieved using bilateral <italic>t</italic>-test and analysis of variance adjusted on baseline value. The global alpha risk level was kept at 5%, according to the a priori ordered hypotheses theory. In addition, sensitivity analysis was performed by variance analysis, with the baseline LVESV value as adjustment factor.</p><p>Patients with a 6 months reduction &#x0003e;15% in LVESV were compared between groups using the <italic>&#x003c7;</italic><sup>2</sup> test. Other criteria were analysed in the ITT population by the use of descriptive statistics and univariate tests (<italic>&#x003c7;</italic><sup>2</sup> test or Fisher's exact test according to expected number in crossings for categorical variables, Kruskal&#x02013;Wallis test for ordinal variables, and analyses of variance on ranked transformed variables for quantitative variables). Changes from baseline were tested by the use of the Wilcoxon sign-rank test. Time to appearance of adverse events was analysed by Kaplan&#x02013;Meier estimates and comparison between groups was made using the log-rank test. As a conservative approach, the last observation carry forward method was used for echocardiographic data and 6 MWT. All statistical analyses were performed using the SAS software version 9.2 (SAS Institute Inc., Cary, NC, USA).</p></sec><sec sec-type="results" id="s9"><title>Results</title><p>A total of 263 patients (72.6% male) were randomized to RVA (<italic>n</italic> = 132) or to RVS (<italic>n</italic> = 131) pacing in 25 centres, 16 in France and 9 in Spain (Appendix) and represent the ITT population. Crossover due to failure of fulfilling the RV implantation criteria in the randomized location was evenly distributed in both arms with two patients crossing over in each group. Two hundred and thirty-one patients reached the end of follow-up (death: <italic>n</italic> = 9, lost to follow-up: <italic>n</italic> = 10, and premature exit: <italic>n</italic> = 13). The mean follow-up was 11.04 &#x000b1; 3.3 months.</p><p>The PP analysis included 182 patients (RVA: <italic>n</italic> = 92) (<italic>Figure <xref ref-type="fig" rid="EHV422F2">2</xref></italic>).
</p><fig id="EHV422F2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Population flowchart.</p></caption><graphic xlink:href="ehv42202"/></fig><p>Patient's characteristics of ITT and PP populations are reported in <italic>Tables <xref ref-type="table" rid="EHV422TB1">1</xref></italic> and <italic><xref ref-type="table" rid="EHV422TB2">2</xref></italic> with no statistical difference between the the groups. Briefly, 72.6% were male, with approximately three of four of non-ischaemic cardiomyopathy and 88.5% were in NYHA class III. The mean age was 63.4 &#x000b1; 9.5 years and the mean LVEF was 30 &#x000b1; 8%.
</p><table-wrap id="EHV422TB1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics of the intention to treat population</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">RVA (132)</th><th align="left" colspan="1" rowspan="1">RVS (131)</th><th align="left" colspan="1" rowspan="1">
<italic>P</italic>-value</th><th align="left" colspan="1" rowspan="1">Total (263)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Men (%)</td><td colspan="1" rowspan="1">74.2</td><td colspan="1" rowspan="1">71.0</td><td colspan="1" rowspan="1">0.582</td><td colspan="1" rowspan="1">72.6</td></tr><tr><td colspan="1" rowspan="1">Age (years)</td><td colspan="1" rowspan="1">63.8 &#x000b1; 9.5</td><td colspan="1" rowspan="1">63.1 &#x000b1; 9.4</td><td colspan="1" rowspan="1">0.583</td><td colspan="1" rowspan="1">63.4 &#x000b1; 9.5</td></tr><tr><td colspan="1" rowspan="1">NYHA class II (%)</td><td colspan="1" rowspan="1">6.9</td><td colspan="1" rowspan="1">7.8</td><td colspan="1" rowspan="3">0.707</td><td colspan="1" rowspan="1">7.3</td></tr><tr><td colspan="1" rowspan="1">NYHA class III (%)</td><td colspan="1" rowspan="1">88.5</td><td colspan="1" rowspan="1">88.4</td><td colspan="1" rowspan="1">88.5</td></tr><tr><td colspan="1" rowspan="1">NYHA class IV ambulatory (%)</td><td colspan="1" rowspan="1">4.6</td><td colspan="1" rowspan="1">3.9</td><td colspan="1" rowspan="1">4.2</td></tr><tr><td colspan="1" rowspan="1">Ischaemic cardiomyopathy (%)</td><td colspan="1" rowspan="1">27.3</td><td colspan="1" rowspan="1">26.0</td><td colspan="1" rowspan="1">0.889</td><td colspan="1" rowspan="1">26.6</td></tr><tr><td colspan="1" rowspan="1">LVEF (%)</td><td colspan="1" rowspan="1">30.0 &#x000b1; 7.7</td><td colspan="1" rowspan="1">29.6 &#x000b1; 8.1</td><td colspan="1" rowspan="1">0.858</td><td colspan="1" rowspan="1">30 &#x000b1; 8</td></tr><tr><td colspan="1" rowspan="1">LVESV (mL)</td><td colspan="1" rowspan="1">154 &#x000b1; 72</td><td colspan="1" rowspan="1">157 &#x000b1; 80</td><td colspan="1" rowspan="1">0.794</td><td colspan="1" rowspan="1">155 &#x000b1; 76</td></tr><tr><td colspan="5" rowspan="1">Baseline medication (%)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Diuretics (%)</td><td colspan="1" rowspan="1">83.3</td><td colspan="1" rowspan="1">86.3</td><td colspan="1" rowspan="1">0.607</td><td colspan="1" rowspan="1">84.8</td></tr><tr><td colspan="1" rowspan="1">&#x02003;ACE inhibitor or ARB (%)</td><td colspan="1" rowspan="1">93.4</td><td colspan="1" rowspan="1">95.6</td><td colspan="1" rowspan="1">0.591</td><td colspan="1" rowspan="1">94.5</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Aldosterone antagonist (%)</td><td colspan="1" rowspan="1">33.3</td><td colspan="1" rowspan="1">37.4</td><td colspan="1" rowspan="1">0.521</td><td colspan="1" rowspan="1">35.4</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Beta-blocker (%)</td><td colspan="1" rowspan="1">88.6</td><td colspan="1" rowspan="1">90.1</td><td colspan="1" rowspan="1">0.842</td><td colspan="1" rowspan="1">89.4</td></tr><tr><td colspan="1" rowspan="1">ICD indication for primary prevention (%)</td><td colspan="1" rowspan="1">98.5</td><td colspan="1" rowspan="1">97.7</td><td colspan="1" rowspan="1">0.684</td><td colspan="1" rowspan="1">98.1</td></tr><tr><td colspan="1" rowspan="1">QRS duration (ms)</td><td colspan="1" rowspan="1">161.2 &#x000b1; 21.4</td><td colspan="1" rowspan="1">161.0 &#x000b1; 22.9</td><td colspan="1" rowspan="1">0.703</td><td colspan="1" rowspan="1">161.1 &#x000b1; 22.1</td></tr><tr><td colspan="1" rowspan="1">&#x02003;&#x0003e;150 ms (%)</td><td colspan="1" rowspan="1">70.1</td><td colspan="1" rowspan="1">65.4</td><td colspan="1" rowspan="1">0.502</td><td colspan="1" rowspan="1">67.7</td></tr><tr><td colspan="1" rowspan="1">LBBB (%)</td><td colspan="1" rowspan="1">81.6</td><td colspan="1" rowspan="1">80.2</td><td colspan="1" rowspan="1">0.856</td><td colspan="1" rowspan="1">80.9</td></tr><tr><td colspan="1" rowspan="1">Intrinsic QRS axis (&#x000b0;)</td><td colspan="1" rowspan="1">&#x02212;11 &#x000b1; 51</td><td colspan="1" rowspan="1">&#x02212;12 &#x000b1; 45</td><td colspan="1" rowspan="1">0.295</td><td colspan="1" rowspan="1">&#x02212;12 &#x000b1; 48</td></tr><tr><td colspan="5" rowspan="1">RV lead procedural data</td></tr><tr><td colspan="1" rowspan="1">&#x02003;R wave (mV)</td><td colspan="1" rowspan="1">14.2 &#x000b1; 6.9</td><td colspan="1" rowspan="1">13.8 &#x000b1; 6.8</td><td colspan="1" rowspan="1">0.581</td><td colspan="1" rowspan="1">14.0 &#x000b1; 6.8</td></tr><tr><td colspan="1" rowspan="1">&#x02003;RV pacing threshold (V/0.5 ms)</td><td colspan="1" rowspan="1">0.8 &#x000b1; 0.3</td><td colspan="1" rowspan="1">0.7 &#x000b1; 0.3</td><td colspan="1" rowspan="1">0.12</td><td colspan="1" rowspan="1">0.8 &#x000b1; 0.3</td></tr><tr><td colspan="1" rowspan="1">&#x02003;RV lead impedance (&#x003a9;)</td><td colspan="1" rowspan="1">676.3 &#x000b1; 146</td><td colspan="1" rowspan="1">761.5 &#x000b1; 171.5</td><td colspan="1" rowspan="1">&#x0003c;0.001</td><td colspan="1" rowspan="1">718.1 &#x000b1; 164.6</td></tr><tr><td colspan="1" rowspan="1">Paced QRS duration (ms)</td><td colspan="1" rowspan="1">140.0 &#x000b1; 26.0</td><td colspan="1" rowspan="1">136.6 &#x000b1; 25.7</td><td colspan="1" rowspan="1">0.201</td><td colspan="1" rowspan="1">132 &#x000b1; 53</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Paced QRS axis (&#x000b0;)</td><td colspan="1" rowspan="1">31 &#x000b1; 136</td><td colspan="1" rowspan="1">62 &#x000b1; 103</td><td colspan="1" rowspan="1">0.06</td><td colspan="1" rowspan="1">47 &#x000b1; 121</td></tr></tbody></table><table-wrap-foot><fn id="TN1"><p>Values are means &#x000b1; SD, or % unless otherwise indicated. All between-groups differences are statistically non-significant except for RV lead impedance.</p></fn><fn id="TN2"><p>NYHA, New York Heart Association; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; LBBB, left bundle block branch.</p></fn></table-wrap-foot></table-wrap><table-wrap id="EHV422TB2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Baseline characteristics of the per protocol population (site implanted)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/></colgroup><thead><tr><th colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">RVA (92)</th><th align="left" colspan="1" rowspan="1">RVS (90)</th><th align="left" colspan="1" rowspan="1">
<italic>P</italic>-value</th><th align="left" colspan="1" rowspan="1">Total (182)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Men (%)</td><td colspan="1" rowspan="1">73.9</td><td colspan="1" rowspan="1">71.1</td><td colspan="1" rowspan="1">0.741</td><td colspan="1" rowspan="1">72.5</td></tr><tr><td colspan="1" rowspan="1">Age (years)</td><td colspan="1" rowspan="1">64.1 &#x000b1; 9.7</td><td colspan="1" rowspan="1">62.5 &#x000b1; 9.8</td><td colspan="1" rowspan="1">0.300</td><td colspan="1" rowspan="1">63.3 &#x000b1; 9.8</td></tr><tr><td colspan="1" rowspan="1">NYHA class II (%)</td><td colspan="1" rowspan="1">5.4</td><td colspan="1" rowspan="1">10.1</td><td colspan="1" rowspan="3">0.376</td><td colspan="1" rowspan="1">7.7</td></tr><tr><td colspan="1" rowspan="1">NYHA class III (%)</td><td colspan="1" rowspan="1">90.2</td><td colspan="1" rowspan="1">85.4</td><td colspan="1" rowspan="1">87.8</td></tr><tr><td colspan="1" rowspan="1">NYHA class IV ambulatory (%)</td><td colspan="1" rowspan="1">4.3</td><td colspan="1" rowspan="1">4.5</td><td colspan="1" rowspan="1">4.4</td></tr><tr><td colspan="1" rowspan="1">Ischaemic cardiomyopathy (%)</td><td colspan="1" rowspan="1">27.2</td><td colspan="1" rowspan="1">25.6</td><td colspan="1" rowspan="1">0.867</td><td colspan="1" rowspan="1">26.4</td></tr><tr><td colspan="1" rowspan="1">LVEF (%)</td><td colspan="1" rowspan="1">29.9 &#x000b1; 7.7</td><td colspan="1" rowspan="1">29.7 &#x000b1; 8.2</td><td colspan="1" rowspan="1">0.940</td><td colspan="1" rowspan="1">30 &#x000b1; 8</td></tr><tr><td colspan="1" rowspan="1">LVESV (mL)</td><td colspan="1" rowspan="1">154 &#x000b1; 72</td><td colspan="1" rowspan="1">158 &#x000b1; 83</td><td colspan="1" rowspan="1">0.734</td><td colspan="1" rowspan="1">156 &#x000b1; 77</td></tr><tr><td colspan="5" rowspan="1">Baseline medication</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Diuretics (%)</td><td colspan="1" rowspan="1">83.7</td><td colspan="1" rowspan="1">86.7</td><td colspan="1" rowspan="1">0.678</td><td colspan="1" rowspan="1">85.2</td></tr><tr><td colspan="1" rowspan="1">&#x02003;ACE inhibitor or ARB (%)</td><td colspan="1" rowspan="1">93.7</td><td colspan="1" rowspan="1">95.7</td><td colspan="1" rowspan="1">0.747</td><td colspan="1" rowspan="1">94.7</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Aldosterone antagonist (%)</td><td colspan="1" rowspan="1">38.0</td><td colspan="1" rowspan="1">40.0</td><td colspan="1" rowspan="1">0.879</td><td colspan="1" rowspan="1">39.0</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Beta-blocker (%)</td><td colspan="1" rowspan="1">90.2</td><td colspan="1" rowspan="1">91.1</td><td colspan="1" rowspan="1">1.000</td><td colspan="1" rowspan="1">90.7</td></tr><tr><td colspan="1" rowspan="1">ICD indication for primary prevention (%)</td><td colspan="1" rowspan="1">98.9</td><td colspan="1" rowspan="1">97.8</td><td colspan="1" rowspan="1">0.619</td><td colspan="1" rowspan="1">98.4</td></tr><tr><td colspan="1" rowspan="1">QRS duration (ms)</td><td colspan="1" rowspan="1">160.1 &#x000b1; 21.4</td><td colspan="1" rowspan="1">159.2 &#x000b1; 23.0</td><td colspan="1" rowspan="1">0.730</td><td colspan="1" rowspan="1">159.6 &#x000b1; 22.1</td></tr><tr><td colspan="1" rowspan="1">&#x02003;&#x0003e;150 ms (%)</td><td colspan="1" rowspan="1">70.8</td><td colspan="1" rowspan="1">62.5</td><td colspan="1" rowspan="1">0.267</td><td colspan="1" rowspan="1">66.7</td></tr><tr><td colspan="1" rowspan="1">LBBB (%)</td><td colspan="1" rowspan="1">85.7</td><td colspan="1" rowspan="1">81.8</td><td colspan="1" rowspan="1">0.643</td><td colspan="1" rowspan="1">83.8</td></tr><tr><td colspan="1" rowspan="1">Intrinsic QRS axis (&#x000b0;)</td><td colspan="1" rowspan="1">&#x02212;12 &#x000b1; 53</td><td colspan="1" rowspan="1">&#x02212;12 &#x000b1; 46</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">&#x02212;12 &#x000b1; 49</td></tr><tr><td colspan="5" rowspan="1">RV lead procedural data</td></tr><tr><td colspan="1" rowspan="1">&#x02003;R wave (mV)</td><td colspan="1" rowspan="1">14.1 &#x000b1; 6.9</td><td colspan="1" rowspan="1">12.9 &#x000b1; 6.5</td><td colspan="1" rowspan="1">0.256</td><td colspan="1" rowspan="1">13.5 &#x000b1; 6.7</td></tr><tr><td colspan="1" rowspan="1">&#x02003;RV pacing threshold (V/0.5 ms)</td><td colspan="1" rowspan="1">0.8 &#x000b1; 0.3</td><td colspan="1" rowspan="1">0.7 &#x000b1; 0.3</td><td colspan="1" rowspan="1">0.035</td><td colspan="1" rowspan="1">0.8 &#x000b1; 0.3</td></tr><tr><td colspan="1" rowspan="1">RV lead impedance (&#x003a9;)</td><td colspan="1" rowspan="1">761 &#x000b1; 175</td><td colspan="1" rowspan="1">682.4 &#x000b1; 165</td><td colspan="1" rowspan="1">&#x0003c;0.001</td><td colspan="1" rowspan="1">721.7 &#x000b1; 174</td></tr><tr><td colspan="1" rowspan="1">Paced QRS duration (ms)</td><td colspan="1" rowspan="1">140.0 &#x000b1; 26.0</td><td colspan="1" rowspan="1">136.6 &#x000b1; 25.7</td><td colspan="1" rowspan="1">0.201</td><td colspan="1" rowspan="1">138.3 &#x000b1; 25.9</td></tr><tr><td colspan="1" rowspan="1">Paced QRS axis (&#x000b0;)</td><td colspan="1" rowspan="1">31 &#x000b1; 136</td><td colspan="1" rowspan="1">56 &#x000b1; 108</td><td colspan="1" rowspan="1">0.16</td><td colspan="1" rowspan="1">44 &#x000b1; 123</td></tr></tbody></table><table-wrap-foot><fn id="TN3"><p>Values are means &#x000b1; SD, or % unless otherwise indicated. All between-groups differences are statistically non-significant except for RV lead impedance.</p></fn><fn id="TN4"><p>NYHA, New York Heart Association; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; LBBB, left bundle block branch.</p></fn></table-wrap-foot></table-wrap><p>The targeted lateral or posterolateral LV lead positions were obtained in 89% of RVS randomized patients and in 91.3% of RVA randomized patients. In total, there was no statistical difference in LV position (<italic>P</italic> = 0.147) within the two groups. The number of epicardial lead was evenly distributed in both groups (three in each group). Implant duration time was 118 &#x000b1; 55 min in the septal group and 112 &#x000b1; 47 min in the apex group (<italic>P</italic> = 0.464), and the fluoroscopic time was 24 &#x000b1; 18 vs. 22 &#x000b1; 19 min, respectively (<italic>P</italic> = 0.175).</p><sec id="s9a"><title>Primary endpoint</title><p>There was no difference in the LVESV at baseline between the two groups in the PP population (157.8 &#x000b1; 82.5 mL in the RVS group and 153.5 &#x000b1; 72.3 mL in the RVA group, <italic>P</italic> = 0.73)<italic>.</italic> The mean LVESV decreased to 132.5 &#x000b1; 85.9 mL (<italic>P</italic> &#x0003c; 0.001) in the RVS group and to 124.2 &#x000b1; 66.9 mL (<italic>P</italic> &#x0003c; 0.001) in the RVA group (<italic>P</italic> = 0.61 between the two groups) at 6 months. The reduction in LVESV was not different between the two groups (&#x02212;25.3 &#x000b1; 39.4 mL in the RVS group and &#x02212;29.3 &#x000b1; 44.5 mL in the RVA group, <italic>P</italic> = 0.79) (<italic>Table <xref ref-type="table" rid="EHV422TB3">3</xref></italic>) with no further significant changes at 12 months (<italic>Table <xref ref-type="table" rid="EHV422TB4">4</xref></italic>). The primary endpoint, i.e. non-inferiority of RVS vs. RVA pacing in the LVESV change between baseline and 6-month follow-up, was reached with the lower limit of the unilateral 97.5% confidence interval equal to &#x02013; 16.36 mL within the &#x02212;20 mL non-inferiority margin with a mean difference = &#x02212;4.06 mL (<italic>P</italic> = 0.006 for non-inferiority). When adjusted on baseline LVESV value, the lower limit of 97.5% confidence interval was &#x02212;16.54 mL (the mean difference &#x02212;4.72 mL, <italic>P</italic> = 0.006 for non-inferiority). In the ITT population, the reduction in LVESV between baseline and 6 months was not different between the two groups (&#x02212;22.4 &#x000b1; 37.3 mL in the RVS group and &#x02212;29.1 &#x000b1; 45.4 mL in the RVA group, <italic>P</italic> = 0.57). The lower bound of the confidence interval is &#x02212;18.36 (<italic>P</italic> for non-inferiority = 0.013). The non-inferiority is also reached (&#x02212;18.37 mL) after adjustment on the LVESV baseline value (<italic>P</italic> for non-inferiority = 0.013).
</p><table-wrap id="EHV422TB3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Echocardiographic measures&#x02014;changes from baseline to 6 months&#x02014;per protocol population</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="2"/><th align="center" colspan="3" rowspan="1">RVA (<italic>n</italic> = 92)<hr/></th><th align="center" colspan="3" rowspan="1">RVS (<italic>n</italic> = 90)<hr/></th><th align="left" colspan="1" rowspan="2">
<italic>P</italic>-value</th></tr><tr><th align="left" colspan="1" rowspan="1">Baseline</th><th align="left" colspan="1" rowspan="1">6 Months</th><th align="left" colspan="1" rowspan="1">Change</th><th align="left" colspan="1" rowspan="1">Baseline</th><th align="left" colspan="1" rowspan="1">6 Months</th><th align="left" colspan="1" rowspan="1">Change</th></tr></thead><tbody><tr><td colspan="8" rowspan="1">LVESV (mL)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Mean &#x000b1; SD</td><td colspan="1" rowspan="1">153.5 &#x000b1; 72.3</td><td colspan="1" rowspan="1">124.2 &#x000b1; 66.9</td><td colspan="1" rowspan="1">&#x02212;29.3 &#x000b1; 44.5</td><td colspan="1" rowspan="1">157.8 &#x000b1; 82.5</td><td colspan="1" rowspan="1">132.5 &#x000b1; 85.9</td><td colspan="1" rowspan="1">&#x02212;25.3 &#x000b1; 39.4</td><td colspan="1" rowspan="1">0.788</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Median</td><td colspan="1" rowspan="1">134.0</td><td colspan="1" rowspan="1">115.0</td><td colspan="1" rowspan="1">&#x02212;20.0</td><td colspan="1" rowspan="1">141.5</td><td colspan="1" rowspan="1">110.0</td><td colspan="1" rowspan="1">&#x02212;19.5</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;Q1; Q3</td><td colspan="1" rowspan="1">105.5; 182.5</td><td colspan="1" rowspan="1">78.0; 154.0</td><td colspan="1" rowspan="1">&#x02212;47.5; 0.0</td><td colspan="1" rowspan="1">106.0; 191.0</td><td colspan="1" rowspan="1">84.0; 163.0</td><td colspan="1" rowspan="1">&#x02212;50.0; 0.0</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="8" rowspan="1">LVESD (mm)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Mean &#x000b1; SD</td><td colspan="1" rowspan="1">62.0 &#x000b1; 11</td><td colspan="1" rowspan="1">58.6 &#x000b1; 13.4</td><td colspan="1" rowspan="1">&#x02212;3.4 &#x000b1; 7.6</td><td colspan="1" rowspan="1">64.8 &#x000b1; 11.8</td><td colspan="1" rowspan="1">61.4 &#x000b1; 13</td><td colspan="1" rowspan="1">&#x02212;3.5 &#x000b1; 7.2</td><td colspan="1" rowspan="1">0.681</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Median</td><td colspan="1" rowspan="1">60.0</td><td colspan="1" rowspan="1">56.5</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">63.5</td><td colspan="1" rowspan="1">61.0</td><td colspan="1" rowspan="1">&#x02212;1.0</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;Q1; Q3</td><td colspan="1" rowspan="1">55.0; 70.0</td><td colspan="1" rowspan="1">50.0; 70.0</td><td colspan="1" rowspan="1">&#x02212;6.0; 0.0</td><td colspan="1" rowspan="1">56.5; 71.0</td><td colspan="1" rowspan="1">52.0; 69.0</td><td colspan="1" rowspan="1">&#x02212;6.0; 0.0</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="8" rowspan="1">LVEDV (mL)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Mean &#x000b1; SD</td><td colspan="1" rowspan="1">215.2 &#x000b1; 84</td><td colspan="1" rowspan="1">189.7 &#x000b1; 77.1</td><td colspan="1" rowspan="1">&#x02212;25.5 &#x000b1; 47</td><td colspan="1" rowspan="1">220.6 &#x000b1; 93.8</td><td colspan="1" rowspan="1">195.3 &#x000b1; 95.8</td><td colspan="1" rowspan="1">&#x02212;25.3 &#x000b1; 47.7</td><td colspan="1" rowspan="1">0.959</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Median</td><td colspan="1" rowspan="1">198.5</td><td colspan="1" rowspan="1">178.0</td><td colspan="1" rowspan="1">&#x02212;19.5</td><td colspan="1" rowspan="1">209.0</td><td colspan="1" rowspan="1">177.5</td><td colspan="1" rowspan="1">&#x02212;18.0</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;Q1; Q3</td><td colspan="1" rowspan="1">159.5; 247.0</td><td colspan="1" rowspan="1">134.0; 229.0</td><td colspan="1" rowspan="1">&#x02212;46.5; 0.0</td><td colspan="1" rowspan="1">156.0; 262.0</td><td colspan="1" rowspan="1">139.0; 227.0</td><td colspan="1" rowspan="1">&#x02212;48.0; 0.0</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="8" rowspan="1">LVEDD (mm)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Mean &#x000b1; SD</td><td colspan="1" rowspan="1">72.2 &#x000b1; 11.3</td><td colspan="1" rowspan="1">69.3 &#x000b1; 12.8</td><td colspan="1" rowspan="1">&#x02212;2.9 &#x000b1; 6.9</td><td colspan="1" rowspan="1">74.1 &#x000b1; 11.4</td><td colspan="1" rowspan="1">71.6 &#x000b1; 11.9</td><td colspan="1" rowspan="1">&#x02212;2.5 &#x000b1; 7.4</td><td colspan="1" rowspan="1">0.925</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Median</td><td colspan="1" rowspan="1">71.0</td><td colspan="1" rowspan="1">68.0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">74.0</td><td colspan="1" rowspan="1">70.0</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;Q1; Q3</td><td colspan="1" rowspan="1">66.0; 77.0</td><td colspan="1" rowspan="1">61.0; 77.0</td><td colspan="1" rowspan="1">&#x02212;8.0; 0.0</td><td colspan="1" rowspan="1">65.5; 81.0</td><td colspan="1" rowspan="1">64.0; 78.0</td><td colspan="1" rowspan="1">&#x02212;5.0; 0.0</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="8" rowspan="1">LVEF (%)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Mean &#x000b1; SD</td><td colspan="1" rowspan="1">30.0 &#x000b1; 7.7</td><td colspan="1" rowspan="1">35.9 &#x000b1; 10.2</td><td colspan="1" rowspan="1">6.0 &#x000b1; 8.7</td><td colspan="1" rowspan="1">29.7 &#x000b1; 8.2</td><td colspan="1" rowspan="1">35.5 &#x000b1; 9.9</td><td colspan="1" rowspan="1">5.8 &#x000b1; 9.1</td><td colspan="1" rowspan="1">0.770</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Median</td><td colspan="1" rowspan="1">30.0</td><td colspan="1" rowspan="1">36.0</td><td colspan="1" rowspan="1">3.0</td><td colspan="1" rowspan="1">30.0</td><td colspan="1" rowspan="1">36.0</td><td colspan="1" rowspan="1">4.0</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;Q1; Q3</td><td colspan="1" rowspan="1">26.0; 34.0</td><td colspan="1" rowspan="1">29.0; 42.0</td><td colspan="1" rowspan="1">0.0; 10.0</td><td colspan="1" rowspan="1">25.0; 35.0</td><td colspan="1" rowspan="1">28.0; 41.0</td><td colspan="1" rowspan="1">0.0; 10.0</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="8" rowspan="1">LV filling time (ms)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Mean &#x000b1; SD</td><td colspan="1" rowspan="1">383.9 &#x000b1; 122.6</td><td colspan="1" rowspan="1">431.8 &#x000b1; 127</td><td colspan="1" rowspan="1">48 &#x000b1; 120</td><td colspan="1" rowspan="1">377.5 &#x000b1; 155.4</td><td colspan="1" rowspan="1">431.2 &#x000b1; 143.8</td><td colspan="1" rowspan="1">53.8 &#x000b1; 133.7</td><td colspan="1" rowspan="1">0.353</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Median</td><td colspan="1" rowspan="1">381.0</td><td colspan="1" rowspan="1">435.0</td><td colspan="1" rowspan="1">29.0</td><td colspan="1" rowspan="1">365.5</td><td colspan="1" rowspan="1">414.0</td><td colspan="1" rowspan="1">50.0</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;Q1; Q3</td><td colspan="1" rowspan="1">284.0; 452.0</td><td colspan="1" rowspan="1">341.0; 525.0</td><td colspan="1" rowspan="1">0.0; 97.0</td><td colspan="1" rowspan="1">275.5; 440.0</td><td colspan="1" rowspan="1">324.0; 512.0</td><td colspan="1" rowspan="1">0.0; 125.5</td><td colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TN5"><p>LVESV, left ventricular end-systolic volume; LVESD, left ventricular end-systolic diameter; LVEDV, left ventricular end-diastolic volume; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction.</p></fn></table-wrap-foot></table-wrap><table-wrap id="EHV422TB4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Echocardiographic measures&#x02014;change from baseline to 12 months&#x02014;per protocol population</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="2"/><th align="center" colspan="3" rowspan="1">RVA (<italic>n</italic> = 92)<hr/></th><th align="center" colspan="3" rowspan="1">RVS (<italic>n</italic> = 90)<hr/></th><th align="left" colspan="1" rowspan="2">
<italic>P</italic>-value</th></tr><tr><th align="left" colspan="1" rowspan="1">Baseline</th><th align="left" colspan="1" rowspan="1">12 Months</th><th align="left" colspan="1" rowspan="1">Change</th><th align="left" colspan="1" rowspan="1">Baseline</th><th align="left" colspan="1" rowspan="1">12 Months</th><th align="left" colspan="1" rowspan="1">Change</th></tr></thead><tbody><tr><td colspan="8" rowspan="1">LVESV (mL)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Mean &#x000b1; SD</td><td colspan="1" rowspan="1">153.5 &#x000b1; 72.3</td><td colspan="1" rowspan="1">114.98 &#x000b1; 67.79</td><td colspan="1" rowspan="1">&#x02212;38.55 &#x000b1; 50.92</td><td colspan="1" rowspan="1">157.8 &#x000b1; 82.5</td><td colspan="1" rowspan="1">125.77 &#x000b1; 88.63</td><td colspan="1" rowspan="1">&#x02212;32.0 &#x000b1; 43.21</td><td colspan="1" rowspan="1">0.472</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Median</td><td colspan="1" rowspan="1">134.0</td><td colspan="1" rowspan="1">104.0</td><td colspan="1" rowspan="1">&#x02212;32.0</td><td colspan="1" rowspan="1">141.5</td><td colspan="1" rowspan="1">105.5</td><td colspan="1" rowspan="1">&#x02212;24.5</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;Q1; Q3</td><td colspan="1" rowspan="1">105.5; 182.5</td><td colspan="1" rowspan="1">68.0; 139.5</td><td colspan="1" rowspan="1">&#x02212;60.5; &#x02212;2.0</td><td colspan="1" rowspan="1">106.0; 191.0</td><td colspan="1" rowspan="1">76.0; 144.0</td><td colspan="1" rowspan="1">&#x02212;58.0; 0.0</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="8" rowspan="1">LVESD (mm)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Mean &#x000b1; SD</td><td colspan="1" rowspan="1">62.0 &#x000b1; 11</td><td colspan="1" rowspan="1">56.70 &#x000b1; 14.16</td><td colspan="1" rowspan="1">&#x02212;5.26 &#x000b1; 8.33</td><td colspan="1" rowspan="1">64.8 &#x000b1; 11.8</td><td colspan="1" rowspan="1">58.72 &#x000b1; 12.91</td><td colspan="1" rowspan="1">&#x02212;6.11 &#x000b1; 8.36</td><td colspan="1" rowspan="1">0.645</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Median</td><td colspan="1" rowspan="1">60.0</td><td colspan="1" rowspan="1">55.5</td><td colspan="1" rowspan="1">&#x02212;2.5</td><td colspan="1" rowspan="1">63.5</td><td colspan="1" rowspan="1">57.0</td><td colspan="1" rowspan="1">&#x02212;4.0</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;Q1; Q3</td><td colspan="1" rowspan="1">55.0; 70.0</td><td colspan="1" rowspan="1">48.0; 67.0</td><td colspan="1" rowspan="1">&#x02212;10.0; 0.0</td><td colspan="1" rowspan="1">56.5; 71.0</td><td colspan="1" rowspan="1">50.0; 67.5</td><td colspan="1" rowspan="1">&#x02212;11.0; 0.0</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="8" rowspan="1">LVEDV (mL)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Mean &#x000b1; SD</td><td colspan="1" rowspan="1">215.2 &#x000b1; 84</td><td colspan="1" rowspan="1">178.08 &#x000b1; 80.6</td><td colspan="1" rowspan="1">&#x02212;37.16 &#x000b1; 55.87</td><td colspan="1" rowspan="1">220.6 &#x000b1; 93.8</td><td colspan="1" rowspan="1">188.01 &#x000b1; 99.03</td><td colspan="1" rowspan="1">&#x02212;32.63 &#x000b1; 53.68</td><td colspan="1" rowspan="1">0.419</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Median</td><td colspan="1" rowspan="1">198.5</td><td colspan="1" rowspan="1">168.0</td><td colspan="1" rowspan="1">&#x02212;34.0</td><td colspan="1" rowspan="1">209.0</td><td colspan="1" rowspan="1">166.0</td><td colspan="1" rowspan="1">&#x02212;21.0</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;Q1; Q3</td><td colspan="1" rowspan="1">159.5; 247.0</td><td colspan="1" rowspan="1">123.0; 211.0</td><td colspan="1" rowspan="1">&#x02212;62.0; 0.0</td><td colspan="1" rowspan="1">156.0; 262.0</td><td colspan="1" rowspan="1">129.0; 215.0</td><td colspan="1" rowspan="1">&#x02212;64.0; 4.0</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="8" rowspan="1">LVEDD (mm)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Mean &#x000b1; SD</td><td colspan="1" rowspan="1">72.2 &#x000b1; 11.3</td><td colspan="1" rowspan="1">68.93 &#x000b1; 13.27</td><td colspan="1" rowspan="1">&#x02212;3.28 &#x000b1; 6.59</td><td colspan="1" rowspan="1">74.1 &#x000b1; 11.4</td><td colspan="1" rowspan="1">69.56 &#x000b1; 12.34</td><td colspan="1" rowspan="1">&#x02212;4.55 &#x000b1; 7.39</td><td colspan="1" rowspan="1">0.515</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Median</td><td colspan="1" rowspan="1">71.0</td><td colspan="1" rowspan="1">67.0</td><td colspan="1" rowspan="1">&#x02212;1.0</td><td colspan="1" rowspan="1">74.0</td><td colspan="1" rowspan="1">68.0</td><td colspan="1" rowspan="1">&#x02212;3.0</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;Q1; Q3</td><td colspan="1" rowspan="1">66.0; 77.0</td><td colspan="1" rowspan="1">60.0; 76.0</td><td colspan="1" rowspan="1">&#x02212;9.0; 0.0</td><td colspan="1" rowspan="1">65.5; 81.0</td><td colspan="1" rowspan="1">60.0; 76.0</td><td colspan="1" rowspan="1">&#x02212;9.0; 0.0</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="8" rowspan="1">LVEF (%)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Mean &#x000b1; SD</td><td colspan="1" rowspan="1">30.0 &#x000b1; 7.7</td><td colspan="1" rowspan="1">38.15 &#x000b1; 11.44</td><td colspan="1" rowspan="1">8.21 &#x000b1; 10.04</td><td colspan="1" rowspan="1">29.7 &#x000b1; 8.2</td><td colspan="1" rowspan="1">36.49 &#x000b1; 10.32</td><td colspan="1" rowspan="1">6.78 &#x000b1; 9.67</td><td colspan="1" rowspan="1">0.722</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Median</td><td colspan="1" rowspan="1">30.0</td><td colspan="1" rowspan="1">39.0</td><td colspan="1" rowspan="1">7.0</td><td colspan="1" rowspan="1">30.0</td><td colspan="1" rowspan="1">36.5</td><td colspan="1" rowspan="1">7.5</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;Q1; Q3</td><td colspan="1" rowspan="1">26.0; 34.0</td><td colspan="1" rowspan="1">30.0; 44.0</td><td colspan="1" rowspan="1">0.0; 13.5</td><td colspan="1" rowspan="1">25.0; 35.0</td><td colspan="1" rowspan="1">30.0; 42.0</td><td colspan="1" rowspan="1">0.0; 14.0</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="8" rowspan="1">LV filling time (ms)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Mean &#x000b1; SD</td><td colspan="1" rowspan="1">383.9 &#x000b1; 122.6</td><td colspan="1" rowspan="1">442.38 &#x000b1; 130.47</td><td colspan="1" rowspan="1">58.52 &#x000b1; 110.94</td><td colspan="1" rowspan="1">377.5 &#x000b1; 155.4</td><td colspan="1" rowspan="1">418.61 &#x000b1; 124.37</td><td colspan="1" rowspan="1">41.16 &#x000b1; 152.75</td><td colspan="1" rowspan="1">0.966</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Median</td><td colspan="1" rowspan="1">381.0</td><td colspan="1" rowspan="1">433.0</td><td colspan="1" rowspan="1">39.0</td><td colspan="1" rowspan="1">365.50</td><td colspan="1" rowspan="1">416.00</td><td colspan="1" rowspan="1">55.0</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;Q1; Q3</td><td colspan="1" rowspan="1">284.0; 452.0</td><td colspan="1" rowspan="1">358.0; 536.0</td><td colspan="1" rowspan="1">&#x02212;10.0; 122.0</td><td colspan="1" rowspan="1">275.5; 440.0</td><td colspan="1" rowspan="1">338.0; 492.0</td><td colspan="1" rowspan="1">&#x02212;11.5; 129.0</td><td colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TN6"><p>LVESV, left ventricular end-systolic volume; LVESD, left ventricular end-systolic diameter; LVEDV, left ventricular end-diastolic volume; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s9b"><title>Secondary endpoints</title><p>The percentage of &#x02018;echo-responders&#x02019; defined by a reduction in LVESV &#x0003e;15% at 6 months was not different (50% in both groups) (<italic>P</italic> = 1.000) in the PP population. Subgroup analysis revealed that none of the following parameters [i.e. age, sex, NYHA class, cardiomyopathy aetiology, intrinsic or paced QRS width or pattern (left bundle block branch (LBBB) or non-LBBB), LVEF, LV volumes] were associated with a further LVESV reduction. None of the studied parameters could predict whether one RV lead position was superior to the other. The implant success rate based on pre-specified RV lead electrical criteria was not inferior in the RVS group when compared with the RVA group (90.0% in RVS vs. 86.8% in RVA; lower limit of 97.5% confidence interval = &#x02212;3.36% &#x0003e; &#x02212;9% threshold). This relative low percentage of fulfilled electrical criteria requirement was mainly due to the non-completion of the defibrillation test (DFT) (<italic>n</italic> = 27) that was mandatory in the study, but not performed by the investigator due to poor haemodynamic status in most cases. Excluding DFT non-completion, the total implant success rate was 99%, with no difference in the two groups. The RV lead procedural data are displayed in <italic>Tables <xref ref-type="table" rid="EHV422TB1">1</xref></italic> and <italic><xref ref-type="table" rid="EHV422TB2">2</xref></italic>. There was no significant change in RV lead characteristics (R wave amplitude, RV pacing threshold and impedance) throughout the follow-up. Procedural or device-related serious adverse events (SAEs) occurred in 68 patients (RVS, <italic>n</italic> = 37) with no difference between the two groups (<italic>P</italic> = 0.401). These SAEs were mainly related to the LV lead (<italic>n</italic> = 30, septal: <italic>n</italic> = 15). The most common LV lead-related SAE was the loss of LV capture (<italic>n</italic> = 16, septal = 9) requiring seven LV lead replacements, septal = 5), eight LV lead repositioning (septal = 4), and one reprogramming (apex). Right ventricular lead SAE occurred in seven patients, three in the septal group and in four in the apical group (<italic>P</italic> = 1.000).</p><p>At baseline, 6 MWT was similar between the two groups (356 &#x000b1; 113 vs. 352 &#x000b1; 115 m, RVS vs. RVA, <italic>P</italic> = 0.750) with a significant increase between baseline and 6 months in both groups (+28 &#x000b1; 85 m, <italic>P</italic> &#x0003c; 0.0001) with no difference between the two groups (<italic>P</italic> = 0.648).</p><p>Although not significant (<italic>P</italic> = 0.056), there was a trend towards a higher percentage of improved patients according to the Milton Packer score in the RVS group (85%) vs. the RVA group (76%).<sup><xref rid="EHV422C24" ref-type="bibr">24</xref></sup></p><p>Nine patients died during the study, five in the RVS group and four in the RVA group (<italic>P</italic> = 0.749) (<italic>Table 5</italic>). The time to first HF hospitalization or death was not different between the two groups (<italic>P</italic> = 0.532) (<italic>Figure <xref ref-type="fig" rid="EHV422F3">3</xref></italic>).
</p><fig id="EHV422F3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Kaplan&#x02013;Meier analysis of survival free from death and heart failure hospitalization in the right ventricular septum vs. right ventricular apex lead implantation group.</p></caption><graphic xlink:href="ehv42203"/></fig></sec></sec><sec sec-type="discussion" id="s10"><title>Discussion</title><p>This study demonstrates that RVS pacing in CRT is not inferior to RVA pacing for LV reverse remodelling with a similar reduction in the LVESV at 6 months. There was also no difference in the clinical outcome with an identical benefit in terms of 6 MWT and Milton Packer composite score. Finally, the composite endpoint including the time to first hospitalization for HF and total mortality was similar in both groups. Implantation success and complication rates were similar for both positions.</p><p>Cardiac resynchronization therapy is a widely accepted therapy for patients with LV systolic dysfunction and wide QRS complex.<sup><xref rid="EHV422C1" ref-type="bibr">1</xref></sup> Clinical success and/or reverse LV remodelling can however only be achieved in 50&#x02013;65% of patients. Among the potential solutions to increase this response rate, the optimal location of the RV lead remains a matter of debate. Apical RV lead position is conventional especially in patients receiving a CRT-D but there are convincing data on the harmful effects of long-term RV apical pacing.<sup><xref rid="EHV422C14" ref-type="bibr">14</xref>,<xref rid="EHV422C16" ref-type="bibr">16</xref></sup></p><p>Several studies assessed the potential benefit of RVS pacing in patients with conventional PM indications, irrespective of LV function.<sup><xref rid="EHV422C1" ref-type="bibr">1</xref></sup> The results of these studies are not uniform but there is a trend towards a beneficial effect of septal pacing. For example, de Cock <italic>et al</italic>.<sup><xref rid="EHV422C28" ref-type="bibr">28</xref></sup> reported the haemodynamic effects of RV outflow tract pacing (septal pacing) in 217 patients included in 9 studies and found a significantly better haemodynamic effect (odds ratio 0.34, confidence interval 0.15, 0.53) of septal pacing compared with conventional RV pacing.</p><p>The feasibility and safety of septal ICD lead positioning have only been recently demonstrated in non-CRT patients. In a prospective study including 215 patients with ICD lead randomized to septal position or to apical position, Mabo <italic>et al</italic>.<sup><xref rid="EHV422C26" ref-type="bibr">26</xref></sup> reported an identical implant success rate, based on strict electrical predefined criteria, in both groups (89.7% in the RVS group vs. 91.7% in the RVA group, <italic>P</italic> = 0.65) with no difference in the defibrillation success rate. In a similar non-CRT population, Kolb <italic>et al</italic>.,<sup><xref rid="EHV422C29" ref-type="bibr">29</xref></sup> however, reported a tendency towards a higher defibrillation threshold in the mid-septal group. Our study confirms the feasibility of septal ICD RV lead implantation in a CRT population. Although non-significant, there was, however, a trend towards a prolongation in the total implant duration and fluoroscopic time in the septal group.</p><p>In CRT recipients, the results of alternative RV pacing sites, mainly septal, have recently been reported but the potential effects of the RV lead position are derived from <italic>post hoc</italic> analysis of large trials.<sup><xref rid="EHV422C12" ref-type="bibr">12</xref>,<xref rid="EHV422C30" ref-type="bibr">30</xref></sup> Thebault <italic>et al</italic>.<sup><xref rid="EHV422C12" ref-type="bibr">12</xref></sup> analysed the influence of RV and LV lead positions. A more favourable CRT outcome with regard to LV reverse remodelling and the composite of time to death or first HF hospitalization was observed when the LV lead was implanted in the lateral wall, away from the LV apex while no difference was observed between RV apical (<italic>n</italic> = 237) and RV non-apical (<italic>n</italic> = 108) lead position. Kutyifa <italic>et al</italic>.<sup><xref rid="EHV422C30" ref-type="bibr">30</xref></sup> retrospectively analysed the influence of the RV lead position on the clinical outcome in 742 of the 1089 CRT patients (68%) included in the MADIT-CRT trial. Right ventricular lead position was classified as apical (<italic>n</italic> = 656) or non-apical (<italic>n</italic> = 86). There was no difference in the primary endpoint (HF or death) in patients with non-apical vs. patients with apical RV lead location (<italic>P</italic> = 0.983). However, a higher risk of VT/VF death (HR 2.45, <italic>P</italic> = 0.003) and VT/VF alone (HR 2.52, <italic>P</italic> = 0.002) predominantly in the first year after device implantation was reported with the non-apical lead position. Similar results with no difference between the two RV lead positions were also reported in small prospective non-randomized trials.<sup><xref rid="EHV422C10" ref-type="bibr">10</xref>,<xref rid="EHV422C17" ref-type="bibr">17&#x02013;21</xref></sup> Kristiansen <italic>et al</italic>.<sup><xref rid="EHV422C22" ref-type="bibr">22</xref></sup> compared two RV lead locations in a prospective single-centre study. They included 85 consecutive CRT patients randomized to RV apex (<italic>n</italic> = 43) or high posterior septal (<italic>n</italic> = 42). They found no difference in terms of LV reverse remodelling at 6 months with a similar proportion of patients with a &#x0003e;15% reduction in LVESV in the RV high posterior septal group (<italic>n</italic> = 25, 64%) and in the RV apex group (<italic>n</italic> = 26, 65%) (<italic>P</italic> = 0.93). The results of the SEPTAL CRT study which included a larger population in a multicentre trial confirm these preliminary results. In other terms, from this study, it appears that in a general population, RV lead position does not appear to be of major importance. The implanting physician should thus implant the lead in the RV position he is the most familiar with. However, rather than an empiric predetermined (septal or apical) RV location, it could be hypothesized that the optimal RV lead location may also be tailored according to the LV position. Indeed, Merchant <italic>et al</italic>.<sup><xref rid="EHV422C31" ref-type="bibr">31</xref></sup> found a significant correlation between LV&#x02013;RV interlead distance and LV lead electrical delay with both parameters acting synergistically in predicting LV anatomic reverse remodelling. Miranda <italic>et al</italic>.<sup><xref rid="EHV422C32" ref-type="bibr">32</xref></sup> prospectively assessed the influence of the RV lead in 50 patients randomized to apical or septal position, on the maximal electrical separation (MES) between the LV and RV leads. Interestingly, MES, commonly associated with a better clinical outcome, was significantly greater in the mid-septum (161 &#x000b1; 23 ms) when compared with the apex (146 &#x000b1; 26 ms) (<italic>P</italic> &#x0003c; 0.001), suggesting the potential favourable effects of chronic septal pacing in CRT recipients. Efforts to optimize both interlead distance and electrical delay may improve CRT outcomes.</p><sec id="s10a"><title>Limitations</title><p>The SEPTAL CRT study has some limitations:
</p><list list-type="simple"><list-item><p>&#x02013;&#x02003;There is a substantial amount of echocardiographic missing data, leading to incomplete results, especially for the primary endpoint. This underlines the difficulties of echo recordings and the feasibility of echo in CRT trials due to technical limitations. On the other hand, the results are strengthened by a core laboratory analysis, and a conservative method was used for the analysis with the Last Carry Forward Value method.</p></list-item><list-item><p>&#x02013;&#x02003;The determination of the anatomical distance and electrical delay between the LV and the RV leads and their potential influences on the change in the LVESV were not prospectively assessed in the present study.</p></list-item></list></sec></sec><sec id="s11"><title>Conclusion</title><p>This study demonstrates that septal RV pacing in CRT is non-inferior to apical RV pacing for LV reverse remodelling at 6 months, with no difference in the clinical outcome. No recommendation for optimal RV lead position can hence be drawn from this study. Further prospective information about the anatomical and electrical relationships between RV and LV lead positions may be one of the next steps in the CRT research agenda.</p></sec><sec id="s12"><title>Funding</title><p>Funding to pay the Open Access publication charges for this article was provided by Boston Scientific.</p><p>
<bold>Conflict of interest:</bold> C.L. reports other from Boston Scientific, during the conduct of the study; personal fees from Boston Scientific, personal fees from Medtronic, personal fees from St. Jude Medical, outside the submitted work. N.S. reports other from Boston Scientific, during the conduct of the study; personal fees from Boston Scientific France, personal fees from Biotronik France, personal fees from Medtronic France, personal fees from St. Jude Medical France, personal fees from Sorin France, outside the submitted work. L.M. reports personal fees from St. Jude Medical, Sorin Group, Biotronik, Medtronic, Boston Scientific, Biosense Webster; grants from St. Jude Medical, Medtronic, Boston Scientific, Biotronik, outside the submitted work. E.M. reports as being employee of Boston Scientific. G.D. reports other from Boston Scientific, during the conduct of the study; non-financial support from Toshiba, other from Servier, personal fees from Sanofi, personal fees from Actelion, outside the submitted work. I.F.-L. reports personal fees from Boston Scientific, personal fees from St. Jude Medical, during the conduct of the study.</p></sec></body><back><ack><title>Acknowledgements</title><p>We acknowledge all of the investigators and research coordinators who participated to the SEPTAL CRT study, as well as those involved from Boston Scientific, including Marie Lambiez as international study coordinator, Maria Paz Lopez-Chicharro as Spanish study coordinator, Carmen Braban and Stephanie Gautier for their study support. We thank Florence Mercier and Colleen Delaney, biostatisticians, for their assistance and critical comments.</p></ack><app-group><app><title>Appendix</title><sec id="s13"><title>The following institutions and investigators participated in the SEPTAL trial</title><sec id="s13a"><title>French centres</title><p>Centre Hospitalier Universitaire Angers: Jean-Marc Dupuis MD, Fr&#x000e9;d&#x000e9;ric Rouleau MD, Aude Tassin MD. Centre Hospitalier Universitaire Haut Lev&#x000ea;que, Bordeaux: Pierre Bordachar MD, Jacques Cl&#x000e9;menty MD, Stephane Lafitte MD, SylvanPloux MD, Patricia Reant MD, Philippe Ritter MD. Centre Hospitalier Universitaire, Grenoble: Pascal Defaye MD, Peggy Jacon MD, Blandine Mondesert MD, Carole Saunier MD, Estelle Vautrin MD. Centre Hospitalier Universitaire, Lille: Salem Kacet MD, Laurence Guedon-Moreau MD, Didier Klug MD, Claude Kouakam MD, Sylvestre Marechaux MD, Christelle Marquie MD, Anne Sophie Polge MD, Marjorie Richardson MD. Centre Hospitalier Universitaire Louis Pradel, Lyon: Philippe Chevallier MD, Brigitte De Breyne MD, Marcin M Lotek MD, Emilie Nonin MD, Julien Pineau MD. Centre Hospitalier Universitaire La Timone Marseille: Jean-Claude Deharo MD, Emilie Bastard MD, Fr&#x000e9;d&#x000e9;ric Franceschi MD, Gilbert Habib MD, Christophe Jego MD, Eric Peyrouse MD, Sebastien Prevot MD. H&#x000f4;pital Saint-Joseph, Marseille: Michel Bremondy MD, Jacques Faure MD, Ange Ferracci MD, Jean Lefevre MD, Andre Pisapia MD. Centre Hospitalier Universitaire, Montpellier: Jean-Marc Davy MD, Frederic Cransac MD, Tien Tri Cung MD, Frederic Georger MD, Jean-Luc Pasquie MD, Franck Raczka MD, Catherine Sportouch-Dukhan MD. Centre Hospitalier Universitaire, Nancy: Nicolas Sadoul MD, Hugues Blangy MD, Jean-Fran&#x000e7;ois Bruntz MD, Luc Freysz MD, Laurent Groben MD, Olivier Huttin MD. Nouvelles Cliniques Nantaises, Nantes: Antoine Bammert MD, Marc Burban MD, Jean-Pierre Cebron MD, Daniel Gras MD. Centre Hospitalier Universitaire La Piti&#x000e9; Salp&#x000ea;tri&#x000e8;re, Paris: Robert Frank MD, Guillaume Duthoit MD, Fran&#x000e7;oise Hidden-Lucet MD, Caroline Himbert MD, Richard Isnard MD, J&#x000e9;r&#x000f4;me Lacotte MD, Fran&#x000e7;oise Pousset MD, ThierryZerah MD. Centre Hospitalier Universitaire, Rennes: Christophe Leclercq MD, Anna&#x000ef;kBellouin MD, Christophe CrocqMD, Christian Deplace MD, Erwan Donal MD, C&#x000e9;cile Hamon MD, Philippe Mabo MD, Olivier Romain MD, Aude Solnon MD. Centre Hospitalier Universitaire, Rouen: Anselme Frederic MD, Fabrice Bauer MD, Mathieu Bernard MD, Benedicte Godin MD, Baptiste Kurtz MD, Arnaud Savoure MD. Centre Cardiologique du Nord, Saint-Denis: Xavier Copie MD, Gilles Lascault MD, Olivier Paziaud MD, Olivier Piot MD, Thierry Touche MD. Centre Hospitalier Universitaire, Toulouse Marc Delay MD, Talia Chilon MD, Nicolas Detis MD, Alexandre Duparc MD, Aur&#x000e9;lien Hebrard MD, Pierre Massabuau MD, Philippe Maury MD, Pierre Mondoly MD, Philippe Rumeau MD. Clinique Pasteur, Toulouse: Serge Boveda MD, Laurence Adrover MD, Nicolas Combes MD, Antoine Deplagne MD, ,Isabelle Marco-Baertich MD, Olivier Fondard MD.</p></sec><sec id="s13b"><title>Spanish centres</title><p>Hospital General Alicante: Juan Gabriel Mart&#x000ed;nez MD, Jos&#x000e9; Luis Iba&#x000f1;ez Criado MD, Diego Ortu&#x000f1;o MD. H. Clinic i Provincial Barcelona: Lluis Mont MD, Antonio Berruezo MD, BeluEduard MD, Ana Mart&#x000ed;n MD, Franco M. Merschon MD, Marta Sitges MD, Jos&#x000e9; Mar&#x000ed;a Tolosana MD, B&#x000e1;rbara Vidal MD. H. Valle Hebron, Barcelona: Angel Moya i Mitjans MD, Oscar Alcalde Rodriguez MD, Jos&#x000e9; Fernando Rodriguez Palomares MD, Nuria Rivas MD, Gisela Teixid&#x000f3; MD. H. Puerta de Hierro Madrid: Ignacio Fern&#x000e1;ndez Lozano MD, Maria Lorena Ruiz Bautista MD, Victor Castro MD, Miguel Angel Cavero MD, Carlos Gutierrez MD, Natalia Ros MD. H. Virgen de la Victoria, Malaga: Francisco Javier Alzueta Rodriguez MD, Fernando Cabrera MD, Alberto Barrera Cordero MD, Jos&#x000e9; Luis Pe&#x000f1;a MD. H. de Valme Sevilla: Juan Lealdel Ojo Gonz&#x000e1;les MD, M&#x000aa; Dolores Garcia Medina MD, Ricardo Pav&#x000f3;n Jim&#x000e9;nez MD, David Villagomez MD. H. Virgen de la Salud Toledo: Eduardo Castellanos Martinez MD, Juan Alcal&#x000e1; MD, Carolina Maicas MD, Miguel Angel Arias Palomares MD, Alberto Puchol MD. H. La F&#x000e9; Valencia: Joaquim OscaAsensi MD, Anastasio Quesada Carmona MD, M&#x000aa; Jos&#x000e9; Sancho-Tello De Carranza MD, Jos&#x000e9; Olag&#x000fc;e De Ros MD, Enrique Castro Pareja MD, Oscar Cano P&#x000e9;rez MD, Ana Osa Saez MD. H. Rio Hortega, Valladolid: Benito HerrerosGuilarte MD, Juan Francisco Mu&#x000f1;oz San Jose MD, Teresa Myriam P&#x000e9;rez Sanz MD.</p></sec><sec id="s13c"><title>Independent event review committee</title><p>Damien Logeart, MD, Centre Hospitalier Universitaire Lariboisi&#x000e8;re, Paris, France.</p><p>Maria Lopez Gil MD, Hospital 12 de Octubre, Madrid, Spain</p></sec><sec id="s13d"><title>Lead position core lab</title><p>Christophe Leclercq MD, Centre Hospitalier Universitaire, Rennes, France; Ignacio Fernandez Lozano MD, H. Puerta de Hierro, Madrid, Spain.</p></sec><sec id="s12e"><title>Echo core lab</title><p>Genevieve Derumeaux MD, PhD, FESC, DHU A-TVB, H&#x000f4;pitalHenri-Mondor, Cr&#x000e9;teil, France.</p></sec></sec></app></app-group><ref-list><title>References</title><ref id="EHV422C1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brignole</surname><given-names>M</given-names></name><name><surname>Auricchio</surname><given-names>A</given-names></name><name><surname>Baron-Esquivias</surname><given-names>G</given-names></name><name><surname>Bordachar</surname><given-names>P</given-names></name><name><surname>Boriani</surname><given-names>G</given-names></name><name><surname>Ole-A Breithardt</surname><given-names>O</given-names></name><name><surname>Cleland</surname><given-names>J</given-names></name><name><surname>Deharo</surname><given-names>JC</given-names></name><name><surname>Delgado</surname><given-names>V</given-names></name><name><surname>Elliott</surname><given-names>PM</given-names></name><name><surname>Gorenek</surname><given-names>B</given-names></name><name><surname>Israel</surname><given-names>CW</given-names></name><name><surname>Leclercq</surname><given-names>C</given-names></name><name><surname>Linde</surname><given-names>C</given-names></name><name><surname>Mont</surname><given-names>L</given-names></name><name><surname>Padeletti</surname><given-names>L</given-names></name><name><surname>Sutton</surname><given-names>R</given-names></name><name><surname>Vardas</surname><given-names>PE</given-names></name></person-group>
<article-title>2013 ESCGuidelines on cardiac pacing and cardiac resynchronization therapy. The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC).Developed in collaboration with the European Heart Rhythm Association (EHRA). 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC).Developed in collaboration with the European Heart Rhythm Association (EHRA)</article-title>. <source>Eur Heart J</source><year>2013</year>;<volume>34</volume>:<fpage>2281</fpage>&#x02013;<lpage>2329</lpage>.<pub-id pub-id-type="pmid">23801822</pub-id></mixed-citation></ref><ref id="EHV422C2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cleland</surname><given-names>JGF</given-names></name><name><surname>Daubert</surname><given-names>JC</given-names></name><name><surname>Erdmann</surname><given-names>E</given-names></name><name><surname>Freemantle</surname><given-names>N</given-names></name><name><surname>Gras</surname><given-names>D</given-names></name><name><surname>Kappenberger</surname><given-names>L</given-names></name><name><surname>Tavazzi</surname><given-names>L</given-names></name></person-group>, <collab>for the Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators</collab>. <article-title>The effect of cardiac resynchronization on morbidity and mortality in heart failure</article-title>. <source>N Engl J Med</source><year>2005</year>;<volume>352</volume>:<fpage>1539</fpage>&#x02013;<lpage>1549</lpage>.<pub-id pub-id-type="pmid">15753115</pub-id></mixed-citation></ref><ref id="EHV422C3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bristow</surname><given-names>MR</given-names></name><name><surname>Saxon</surname><given-names>LA</given-names></name><name><surname>Boehmer</surname><given-names>J</given-names></name><name><surname>Krueger</surname><given-names>S</given-names></name><name><surname>Kass</surname><given-names>DA</given-names></name><name><surname>De Marco</surname><given-names>T</given-names></name><name><surname>Carson</surname><given-names>P</given-names></name><name><surname>DiCarlo</surname><given-names>L</given-names></name><name><surname>Demets</surname><given-names>D</given-names></name><name><surname>White</surname><given-names>BG</given-names></name><name><surname>DeVries</surname><given-names>DW</given-names></name><name><surname>Feldman</surname><given-names>AM</given-names></name></person-group>, <collab>for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators</collab>. <article-title>Cardiac-resynchronization therapy with or without an implantable defibrillation advanced chronic heart failure</article-title><italic>.</italic><source>N Engl J Med</source><year>2004</year>;<volume>350</volume>:<fpage>2140</fpage>&#x02013;<lpage>2150</lpage>.<pub-id pub-id-type="pmid">15152059</pub-id></mixed-citation></ref><ref id="EHV422C4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tang</surname><given-names>AS</given-names></name><name><surname>Wells</surname><given-names>GA</given-names></name><name><surname>Talajic</surname><given-names>M</given-names></name><name><surname>Arnold</surname><given-names>MO</given-names></name><name><surname>Sheldon</surname><given-names>R</given-names></name><name><surname>Connolly</surname><given-names>S</given-names></name><name><surname>Hohnloser</surname><given-names>SH</given-names></name><name><surname>Nichol</surname><given-names>G</given-names></name><name><surname>Birnie</surname><given-names>DH</given-names></name><name><surname>Sapp</surname><given-names>JL</given-names></name><name><surname>Yee</surname><given-names>R</given-names></name><name><surname>Healey</surname><given-names>JS</given-names></name><name><surname>Rouleau</surname><given-names>JL</given-names></name></person-group>
<article-title>Cardiac-resynchronization therapy for mild-to-moderate heart failure</article-title><italic>.</italic><source>N Engl J Med</source><year>2010</year>;<volume>363</volume>:<fpage>2385</fpage>&#x02013;<lpage>2395</lpage>.<pub-id pub-id-type="pmid">21073365</pub-id></mixed-citation></ref><ref id="EHV422C5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zareba</surname><given-names>W</given-names></name><name><surname>Klein</surname><given-names>H</given-names></name><name><surname>Cygankiewicz</surname><given-names>I</given-names></name><name><surname>Hall</surname><given-names>WJ</given-names></name><name><surname>McNitt</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Cannom</surname><given-names>D</given-names></name><name><surname>Daubert</surname><given-names>JP</given-names></name><name><surname>Eldar</surname><given-names>M</given-names></name><name><surname>Gold</surname><given-names>MR</given-names></name><name><surname>Goldberger</surname><given-names>JJ</given-names></name><name><surname>Goldenberg</surname><given-names>I</given-names></name><name><surname>Lichstein</surname><given-names>E</given-names></name><name><surname>Pitschner</surname><given-names>H</given-names></name><name><surname>Rashtian</surname><given-names>M</given-names></name><name><surname>Solomon</surname><given-names>S</given-names></name><name><surname>Viskin</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Moss</surname><given-names>AJ</given-names></name></person-group>
<article-title>Effectiveness of cardiac resynchronization therapy by QRS morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT)</article-title>. <source>Circulation</source><year>2011</year>;<volume>123</volume>:<fpage>1061</fpage>&#x02013;<lpage>1072</lpage>.<pub-id pub-id-type="pmid">21357819</pub-id></mixed-citation></ref><ref id="EHV422C6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gervais</surname><given-names>R</given-names></name><name><surname>Leclercq</surname><given-names>C</given-names></name><name><surname>Shankar</surname><given-names>A</given-names></name><name><surname>Jacobs</surname><given-names>S</given-names></name><name><surname>Eiskj&#x000e6;r</surname><given-names>H</given-names></name><name><surname>Johannessen</surname><given-names>A</given-names></name><name><surname>Freemantle</surname><given-names>N</given-names></name><name><surname>Cleland</surname><given-names>JGF</given-names></name><name><surname>Tavazzi</surname><given-names>L</given-names></name><name><surname>Daubert</surname><given-names>C</given-names></name></person-group>
<article-title>Surface electrocardiogram to predict outcome in candidates for cardiac resynchronization therapy: a sub-analysis of the CARE-HF trial</article-title>. <source>Eur J Heart Fail</source><year>2009</year>;<volume>11</volume>:<fpage>699</fpage>&#x02013;<lpage>705</lpage>.<pub-id pub-id-type="pmid">19505883</pub-id></mixed-citation></ref><ref id="EHV422C7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cleland</surname><given-names>JC</given-names></name><name><surname>Abraham</surname><given-names>WT</given-names></name><name><surname>Linde</surname><given-names>C</given-names></name><name><surname>Gold</surname><given-names>MR</given-names></name><name><surname>Young</surname><given-names>JB</given-names></name><name><surname>Daubert</surname><given-names>JC</given-names></name><name><surname>Sherfesee</surname><given-names>L</given-names></name><name><surname>Wells</surname><given-names>GA</given-names></name><name><surname>Tang</surname><given-names>ASL</given-names></name></person-group>
<article-title>An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure</article-title>. <source>Eur Heart J</source><year>2013</year>;<volume>34</volume>:<fpage>3547</fpage>&#x02013;<lpage>3556</lpage>.<pub-id pub-id-type="pmid">23900696</pub-id></mixed-citation></ref><ref id="EHV422C8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Burri</surname><given-names>H</given-names></name><name><surname>Domenichini</surname><given-names>G</given-names></name><name><surname>Sunthorn</surname><given-names>H</given-names></name><name><surname>Fleury</surname><given-names>E</given-names></name><name><surname>Stettler</surname><given-names>C</given-names></name><name><surname>Foulkes</surname><given-names>I</given-names></name><name><surname>Shah</surname><given-names>D</given-names></name></person-group>
<article-title>Right ventricular systolic function and cardiac resynchronization therapy</article-title>. <source>Europace</source><year>2010</year>;<volume>12</volume>:<fpage>389</fpage>&#x02013;<lpage>394</lpage>.<pub-id pub-id-type="pmid">19966321</pub-id></mixed-citation></ref><ref id="EHV422C9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ypenburg</surname><given-names>C</given-names></name><name><surname>van Bommel</surname><given-names>RJ</given-names></name><name><surname>Delgado</surname><given-names>V</given-names></name><name><surname>Mollema</surname><given-names>SA</given-names></name><name><surname>Bleeker</surname><given-names>GB</given-names></name><name><surname>Boersma</surname><given-names>E</given-names></name><name><surname>Schalij</surname><given-names>MJ</given-names></name><name><surname>Bax</surname><given-names>JJ</given-names></name></person-group>
<article-title>Optimal left ventricular lead position predicts reverse remodeling and survival after cardiac resynchronization therapy</article-title>. <source>J Am Coll Cardiol</source><year>2008</year>;<volume>52</volume>:<fpage>1402</fpage>&#x02013;<lpage>1409</lpage>.<pub-id pub-id-type="pmid">18940531</pub-id></mixed-citation></ref><ref id="EHV422C10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khan</surname><given-names>FZ</given-names></name><name><surname>Virdee</surname><given-names>MS</given-names></name><name><surname>Palmer</surname><given-names>CR</given-names></name><name><surname>Pugh</surname><given-names>PJ</given-names></name><name><surname>Halloran</surname><given-names>DO</given-names></name><name><surname>Elsik</surname><given-names>M</given-names></name><name><surname>Read</surname><given-names>PA</given-names></name><name><surname>Begley</surname><given-names>D</given-names></name><name><surname>Fynn</surname><given-names>SP</given-names></name><name><surname>Dutka</surname><given-names>DP</given-names></name></person-group>
<article-title>Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET Study: a randomized, controlled trial</article-title>. <source>J Am Coll Cardiol</source><year>2012</year>;<volume>59</volume>:<fpage>1509</fpage>&#x02013;<lpage>1518</lpage>.<pub-id pub-id-type="pmid">22405632</pub-id></mixed-citation></ref><ref id="EHV422C11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singh</surname><given-names>JP</given-names></name><name><surname>Klein</surname><given-names>HU</given-names></name><name><surname>Huang</surname><given-names>DT</given-names></name><name><surname>Reek</surname><given-names>S</given-names></name><name><surname>Kuniss</surname><given-names>M</given-names></name><name><surname>Quesada</surname><given-names>A</given-names></name><name><surname>Barsheshet</surname><given-names>A</given-names></name><name><surname>Cannom</surname><given-names>D</given-names></name><name><surname>Goldenberg</surname><given-names>I</given-names></name><name><surname>McNitt</surname><given-names>S</given-names></name><name><surname>Daubertert</surname><given-names>JP</given-names></name><name><surname>Zareba</surname><given-names>W</given-names></name><name><surname>Moss</surname><given-names>AJ.</given-names></name></person-group>
<article-title>Left ventricular lead position and clinical outcome in the Multicenter Automatic Defibrillator Implantation Trial&#x02013;Cardiac Resynchronization Therapy (MADIT-CRT) Trial</article-title>. <source>Circulation</source><year>2011</year>;<volume>123</volume>:<fpage>1159</fpage>&#x02013;<lpage>1166</lpage>.<pub-id pub-id-type="pmid">21382893</pub-id></mixed-citation></ref><ref id="EHV422C12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thebault</surname><given-names>C</given-names></name><name><surname>Donal</surname><given-names>E</given-names></name><name><surname>Meunier</surname><given-names>C</given-names></name><name><surname>Gervais</surname><given-names>R</given-names></name><name><surname>Gerritse</surname><given-names>B</given-names></name><name><surname>Gold</surname><given-names>MR</given-names></name><name><surname>Abraham</surname><given-names>WT</given-names></name><name><surname>Linde</surname><given-names>C</given-names></name><name><surname>Daubert</surname><given-names>JC</given-names></name></person-group>
<article-title>Sites of left and right ventricular lead implantation and response to cardiac resynchronization therapy observations from the REVERSE trial</article-title>. <source>Eur Heart J</source><year>2012</year>;<volume>33</volume>:<fpage>2662</fpage>&#x02013;<lpage>2671</lpage>.<pub-id pub-id-type="pmid">22285578</pub-id></mixed-citation></ref><ref id="EHV422C13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Daubert</surname><given-names>JC</given-names></name><name><surname>Saxon</surname><given-names>L</given-names></name><name><surname>Adamson</surname><given-names>PB</given-names></name><name><surname>Auricchio</surname><given-names>A</given-names></name><name><surname>Berger</surname><given-names>RD</given-names></name><name><surname>Beshai</surname><given-names>JF</given-names></name><name><surname>Breithard</surname><given-names>O</given-names></name><name><surname>Brignole</surname><given-names>M</given-names></name><name><surname>Cleland</surname><given-names>J</given-names></name><name><surname>Delurgio</surname><given-names>DB</given-names></name><name><surname>Dickstein</surname><given-names>K</given-names></name><name><surname>Exner</surname><given-names>DV</given-names></name><name><surname>Gold</surname><given-names>M</given-names></name><name><surname>Grimm</surname><given-names>RA</given-names></name><name><surname>Hayes</surname><given-names>DL</given-names></name><name><surname>Israel</surname><given-names>C</given-names></name><name><surname>Leclercq</surname><given-names>C</given-names></name><name><surname>Linde</surname><given-names>C</given-names></name><name><surname>Lindenfeld</surname><given-names>J</given-names></name><name><surname>Merkely</surname><given-names>B</given-names></name><name><surname>Mont</surname><given-names>L</given-names></name><name><surname>Murgatroyd</surname><given-names>F</given-names></name><name><surname>Prinzen</surname><given-names>F</given-names></name><name><surname>Saba</surname><given-names>SF</given-names></name><name><surname>Shinbane</surname><given-names>JS</given-names></name><name><surname>Singh</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>AS</given-names></name><name><surname>Vardas</surname><given-names>PE</given-names></name><name><surname>Wilkoff</surname><given-names>BL</given-names></name><name><surname>Zamorano</surname><given-names>JL</given-names></name><name><surname>Anand</surname><given-names>I</given-names></name><name><surname>Blomstrom-Lundqvist</surname><given-names>C</given-names></name><name><surname>Boehmer</surname><given-names>JP</given-names></name><name><surname>Calkins</surname><given-names>H</given-names></name><name><surname>Cazeau</surname><given-names>S</given-names></name><name><surname>Delgado</surname><given-names>V</given-names></name><name><surname>Estes</surname><given-names>NA</given-names></name><name><surname>Haines</surname><given-names>D</given-names></name><name><surname>Kusumoto</surname><given-names>F</given-names></name><name><surname>Leyva</surname><given-names>P</given-names></name><name><surname>Ruschitzka</surname><given-names>F</given-names></name><name><surname>Stevenson</surname><given-names>LW</given-names></name><name><surname>Torp-Pedersen</surname><given-names>CT</given-names></name></person-group>
<article-title>2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. A registered branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society; and in collaboration with the Heart Failure Society of America (HFSA), the American Society of Echocardiography (ASE), the American Heart Association (AHA), the European Association of Echocardiography (EAE) of the ESC and the Heart Failure Association of the ESC (HFA). Endorsed by the governing bodies of AHA, ASE, EAE, HFSA, HFA, EHRA, and HRS</article-title><source>. Europace</source><year>2012</year>;<volume>14</volume>:<fpage>1236</fpage>&#x02013;<lpage>1286</lpage>.<pub-id pub-id-type="pmid">22930717</pub-id></mixed-citation></ref><ref id="EHV422C14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wilkoff</surname><given-names>BL</given-names></name><name><surname>Cook</surname><given-names>JR</given-names></name><name><surname>Epstein</surname><given-names>AE</given-names></name><name><surname>Greene</surname><given-names>HL</given-names></name><name><surname>Hallstrom</surname><given-names>AP</given-names></name><name><surname>Hsia</surname><given-names>H</given-names></name><name><surname>Kutalek</surname><given-names>SP</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name></person-group>
<article-title>Dual chamber and VVI implantable defibrillator trial investigators</article-title>. <source>JAMA</source><year>2002</year>;<volume>288</volume>:<fpage>3115</fpage>&#x02013;<lpage>3123</lpage>.<pub-id pub-id-type="pmid">12495391</pub-id></mixed-citation></ref><ref id="EHV422C15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barsheshet</surname><given-names>A</given-names></name><name><surname>Moss</surname><given-names>AJ</given-names></name><name><surname>McNitt</surname><given-names>S</given-names></name><name><surname>Jons</surname><given-names>C</given-names></name><name><surname>Glikson</surname><given-names>M</given-names></name><name><surname>Klein</surname><given-names>HU</given-names></name><name><surname>Huang</surname><given-names>DT</given-names></name><name><surname>Steinberg</surname><given-names>JS</given-names></name><name><surname>Brown</surname><given-names>MW</given-names></name><name><surname>Zareba</surname><given-names>W</given-names></name><name><surname>Goldenberg</surname><given-names>I</given-names></name></person-group>, <collab>MADIT-II Executive Committee</collab>. <article-title>Long-term implications of cumulative right ventricular pacing among patients with an implantable cardioverter-defibrillator</article-title>. <source>Heart Rhythm</source><year>2011</year>;<volume>8</volume>:<fpage>212</fpage>&#x02013;<lpage>218</lpage>.<pub-id pub-id-type="pmid">21044897</pub-id></mixed-citation></ref><ref id="EHV422C16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>JS</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Schuger</surname><given-names>C</given-names></name><name><surname>Daubert</surname><given-names>J</given-names></name><name><surname>Mcnitt</surname><given-names>S</given-names></name><name><surname>Andrews</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Hall</surname><given-names>WL</given-names></name><name><surname>Zareba</surname><given-names>W</given-names></name><name><surname>Moss</surname><given-names>AJ</given-names></name></person-group>, <collab>for MADIT II investigators</collab>. <article-title>The clinical implications of cumulative right ventricular pacing in the Multicenter Automatic Defibrillator Trial II</article-title>. <source>J Cardiovasc Electrophysiol</source><year>2005</year>;<volume>16</volume>:<fpage>359</fpage>&#x02013;<lpage>365</lpage>.<pub-id pub-id-type="pmid">15828875</pub-id></mixed-citation></ref><ref id="EHV422C17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Riedlbauchova</surname><given-names>L</given-names></name><name><surname>Cihak</surname><given-names>R</given-names></name><name><surname>Bytesnik</surname><given-names>J</given-names></name><name><surname>Vancura</surname><given-names>V</given-names></name><name><surname>Fridl</surname><given-names>P</given-names></name><name><surname>Hoskova</surname><given-names>L</given-names></name><name><surname>Kautzner</surname><given-names>J</given-names></name></person-group>
<article-title>Optimization of right ventricular lead position in cardiac resynchronisation therapy</article-title>. <source>Eur J Heart Fail</source><year>2006</year>;<volume>8</volume>:<fpage>609</fpage>&#x02013;<lpage>614</lpage>.<pub-id pub-id-type="pmid">16504581</pub-id></mixed-citation></ref><ref id="EHV422C18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haghjoo</surname><given-names>M</given-names></name><name><surname>Bonakdar</surname><given-names>HR</given-names></name><name><surname>Jorat</surname><given-names>MV</given-names></name><name><surname>Fazelifar</surname><given-names>AF</given-names></name><name><surname>Alizadeh</surname><given-names>A</given-names></name><name><surname>Ojaghi-Haghjghi</surname><given-names>Z</given-names></name><name><surname>Esmaielzadeh</surname><given-names>M</given-names></name><name><surname>Sadr-Ameli</surname><given-names>MA</given-names></name></person-group>
<article-title>Effect of right ventricular lead location on response to cardiac resynchronization therapy in patients with end-stage heart failure</article-title>. <source>Europace</source><year>2009</year>;<volume>11</volume>:<fpage>356</fpage>&#x02013;<lpage>363</lpage>.<pub-id pub-id-type="pmid">19136489</pub-id></mixed-citation></ref><ref id="EHV422C19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hay</surname><given-names>I</given-names></name><name><surname>Melenovsky</surname><given-names>V</given-names></name><name><surname>Fetics</surname><given-names>BJ</given-names></name><name><surname>Judge</surname><given-names>DP</given-names></name><name><surname>Kramer</surname><given-names>A</given-names></name><name><surname>Spinelli</surname><given-names>J</given-names></name><name><surname>Reister</surname><given-names>C</given-names></name><name><surname>Kass</surname><given-names>DA</given-names></name><name><surname>Berger</surname><given-names>RD</given-names></name></person-group>
<article-title>Short-term effects of right-left heart sequential cardiac resynchronization in patients with heart failure, chronic atrial fibrillation, and atrioventricular nodal block</article-title>. <source>Circulation</source><year>2004</year>;<volume>110</volume>:<fpage>3404</fpage>&#x02013;<lpage>3410</lpage>.<pub-id pub-id-type="pmid">15557370</pub-id></mixed-citation></ref><ref id="EHV422C20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bulava</surname><given-names>A</given-names></name><name><surname>Lukl</surname><given-names>J</given-names></name></person-group>
<article-title>Similar long-term benefits conferred by apical versus mid-septal implantation of the right ventricular lead in recipients of cardiac resynchronization therapy systems</article-title>. <source>Pacing Clin Electrophysiol</source><year>2009</year>;<volume>32</volume>:<fpage>S32</fpage>&#x02013;<lpage>S37</lpage>.</mixed-citation></ref><ref id="EHV422C21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shimano</surname><given-names>M</given-names></name><name><surname>Inden</surname><given-names>Y</given-names></name><name><surname>Yoshida</surname><given-names>Y</given-names></name><name><surname>Tsuji</surname><given-names>Y</given-names></name><name><surname>Tsuboi</surname><given-names>N</given-names></name><name><surname>Okada</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Murakami</surname><given-names>Y</given-names></name><name><surname>Takada</surname><given-names>Y</given-names></name><name><surname>Hirayama</surname><given-names>H</given-names></name><name><surname>Murohara</surname><given-names>T</given-names></name></person-group>
<article-title>Does RV Lead Positioning Provide Additional Benefit to Cardiac Resynchronization Therapy in Patients with Advanced Heart Failure?</article-title><source>Pacing Clin Electrophysiol</source><year>2006</year>;<volume>29</volume>:<fpage>1069</fpage>&#x02013;<lpage>1074</lpage>.<pub-id pub-id-type="pmid">17038138</pub-id></mixed-citation></ref><ref id="EHV422C22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kristiansen</surname><given-names>HM</given-names></name><name><surname>Vollan</surname><given-names>G</given-names></name><name><surname>Hovstad</surname><given-names>T</given-names></name><name><surname>Keilegavlen</surname><given-names>H</given-names></name><name><surname>Faerestrand</surname><given-names>S</given-names></name></person-group>
<article-title>A randomized study of haemodynamic effects and left ventricular dyssynchrony in right ventricular apical vs. high posterior septal pacing in cardiac resynchronization therapy</article-title>. <source>Eur J Heart Fail</source><year>2012</year>;<volume>14</volume>:<fpage>506</fpage>&#x02013;<lpage>519</lpage>.<pub-id pub-id-type="pmid">22286156</pub-id></mixed-citation></ref><ref id="EHV422C23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Packer</surname><given-names>M</given-names></name></person-group>
<article-title>Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure</article-title>. <source>J Card Fail</source><year>2001</year>;<volume>7</volume>:<fpage>176</fpage>&#x02013;<lpage>182</lpage>.<pub-id pub-id-type="pmid">11420770</pub-id></mixed-citation></ref><ref id="EHV422C24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dickstein</surname><given-names>K</given-names></name><name><surname>Cohen-Solal</surname><given-names>A</given-names></name><name><surname>Filippatos</surname><given-names>G</given-names></name><name><surname>McMurray</surname><given-names>JJ</given-names></name><name><surname>Ponikowski</surname><given-names>P</given-names></name><name><surname>Poole-Wilson</surname><given-names>PA</given-names></name><name><surname>Stromberg</surname><given-names>A</given-names></name><name><surname>van Veldhuisen</surname><given-names>DJ</given-names></name><name><surname>Atar</surname><given-names>D</given-names></name><name><surname>Hoes</surname><given-names>AW</given-names></name><name><surname>Keren</surname><given-names>A</given-names></name><name><surname>Mebazaa</surname><given-names>A</given-names></name><name><surname>Nieminen</surname><given-names>M</given-names></name><name><surname>Priori</surname><given-names>SG</given-names></name><name><surname>Swedberg</surname><given-names>K</given-names></name><name><surname>Vahanian</surname><given-names>A</given-names></name><name><surname>Camm</surname><given-names>J</given-names></name><name><surname>De Caterina</surname><given-names>R</given-names></name><name><surname>Dean</surname><given-names>V</given-names></name><name><surname>Dickstein</surname><given-names>K</given-names></name><name><surname>Filippatos</surname><given-names>G</given-names></name><name><surname>Funck-Brentano</surname><given-names>C</given-names></name><name><surname>Hellemans</surname><given-names>I</given-names></name><name><surname>Kristensen</surname><given-names>SD</given-names></name><name><surname>McGregor</surname><given-names>K</given-names></name><name><surname>Sechtem</surname><given-names>U</given-names></name><name><surname>Silber</surname><given-names>S</given-names></name><name><surname>Tendera</surname><given-names>M</given-names></name><name><surname>Widimsky</surname><given-names>P</given-names></name><name><surname>Zamorano</surname><given-names>JL</given-names></name></person-group>
<article-title>ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)</article-title>. <source>Eur Heart J</source><year>2008</year>;<volume>29</volume>:<fpage>2388</fpage>&#x02013;<lpage>2442</lpage>.<pub-id pub-id-type="pmid">18799522</pub-id></mixed-citation></ref><ref id="EHV422C25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dickstein</surname><given-names>K</given-names></name><name><surname>Vardas</surname><given-names>PE</given-names></name><name><surname>Angelo Auricchio</surname><given-names>A</given-names></name><name><surname>Daubert</surname><given-names>JC</given-names></name><name><surname>Linde</surname><given-names>C</given-names></name><name><surname>McMurray</surname><given-names>J</given-names></name><name><surname>Ponikowski</surname><given-names>P</given-names></name><name><surname>Priori</surname><given-names>SG</given-names></name><name><surname>Sutton</surname><given-names>R</given-names></name><name><surname>van Veldhuisen</surname><given-names>DJ</given-names></name></person-group>
<article-title>2010 Focused Update of ESC guidelines on device therapy in heart failure An update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapyDeveloped with the special contribution of the Heart Failure Association and the European Heart Rhythm Association</article-title>. <source>Eur Heart J</source><year>2010</year>;<volume>31</volume>:<fpage>2677</fpage>&#x02013;<lpage>2687</lpage>.<pub-id pub-id-type="pmid">20801924</pub-id></mixed-citation></ref><ref id="EHV422C26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mabo</surname><given-names>P</given-names></name><name><surname>Defaye</surname><given-names>P</given-names></name><name><surname>Mouton</surname><given-names>E</given-names></name><name><surname>Cebron</surname><given-names>JP</given-names></name><name><surname>Davy</surname><given-names>JM</given-names></name><name><surname>Tassin</surname><given-names>A</given-names></name><name><surname>Babuty</surname><given-names>D</given-names></name><name><surname>Mondoly</surname><given-names>P</given-names></name><name><surname>Paziaud</surname><given-names>O</given-names></name><name><surname>Anselme</surname><given-names>F</given-names></name><name><surname>Daubert</surname><given-names>JC</given-names></name></person-group>
<article-title>A randomized study of defibrillator lead implantations in the right ventricular mid-septum versus the apex: the SEPTAL study</article-title>. <source>J Cardiovasc Electrophysiol</source><year>2012</year>;<volume>23</volume>:<fpage>853</fpage>&#x02013;<lpage>860</lpage>.<pub-id pub-id-type="pmid">22452288</pub-id></mixed-citation></ref><ref id="EHV422C27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ernande</surname><given-names>L</given-names></name><name><surname>Bergerot</surname><given-names>C</given-names></name><name><surname>Girerd</surname><given-names>N</given-names></name><name><surname>Thibault</surname><given-names>H</given-names></name><name><surname>Davidsen</surname><given-names>ES</given-names></name><name><surname>Gautier Pignon-Blanc</surname><given-names>P</given-names></name><name><surname>Amaz</surname><given-names>C</given-names></name><name><surname>Croisille</surname><given-names>P</given-names></name><name><surname>De Buyzere</surname><given-names>ML</given-names></name><name><surname>Rietzschel</surname><given-names>ER</given-names></name><name><surname>Gillebert</surname><given-names>TC</given-names></name><name><surname>Moulin</surname><given-names>P</given-names></name><name><surname>Altman</surname><given-names>M</given-names></name><name><surname>Derumeaux</surname><given-names>G</given-names></name></person-group>
<article-title>Longitudinal myocardial strain alteration is associated with left ventricular remodeling in asymptomatic patients with type 2 diabetes mellitus</article-title>. <source>J Am Soc Echocardiogr</source><year>2014</year>;<volume>24</volume>:<fpage>479</fpage>&#x02013;<lpage>487</lpage>.</mixed-citation></ref><ref id="EHV422C28"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Cock</surname><given-names>CC</given-names></name><name><surname>Giudici</surname><given-names>MC</given-names></name><name><surname>Twisk</surname><given-names>JW</given-names></name></person-group>
<article-title>Comparison of the haemodynamic effects of right ventricular outflow-tract pacing with right ventricular apex pacing. A quantitative review</article-title>. <source>Europace</source><year>2003</year>;<volume>5</volume>:<fpage>275</fpage>&#x02013;<lpage>278</lpage>.<pub-id pub-id-type="pmid">12842643</pub-id></mixed-citation></ref><ref id="EHV422C29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kolb</surname><given-names>C</given-names></name><name><surname>Solzbach</surname><given-names>U</given-names></name><name><surname>Biermann</surname><given-names>J</given-names></name><name><surname>Semmler</surname><given-names>V</given-names></name><name><surname>Kloppe</surname><given-names>A</given-names></name><name><surname>Klein</surname><given-names>N</given-names></name><name><surname>Lennerz</surname><given-names>C</given-names></name><name><surname>Szendey</surname><given-names>I</given-names></name><name><surname>Andrikopoulos</surname><given-names>G</given-names></name><name><surname>Tzeis</surname><given-names>S</given-names></name><name><surname>Asbach</surname><given-names>S</given-names></name></person-group>, <collab>for the SPICE-investigators. Safety of mid-septal electrode placement in implantable cardioverter defibrillator recipients&#x02014;results of the SPICE (Septal Positioning of ventricular ICD Electrodes) study</collab>. <source>Int J Cardiol</source><year>2014</year>;<volume>174</volume>:<fpage>713</fpage>&#x02013;<lpage>720</lpage>.<pub-id pub-id-type="pmid">24838056</pub-id></mixed-citation></ref><ref id="EHV422C30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kutyifa</surname><given-names>V</given-names></name><name><surname>Bloch Thomsen</surname><given-names>PE</given-names></name><name><surname>Huang</surname><given-names>DT</given-names></name><name><surname>Rosero</surname><given-names>S</given-names></name><name><surname>Tompkins</surname><given-names>C</given-names></name><name><surname>Jons</surname><given-names>C</given-names></name><name><surname>McNitt</surname><given-names>S</given-names></name><name><surname>Polonsky</surname><given-names>B</given-names></name><name><surname>Shah</surname><given-names>A</given-names></name><name><surname>Merkely</surname><given-names>B</given-names></name><name><surname>Solomon</surname><given-names>SD</given-names></name><name><surname>Moss</surname><given-names>AJ</given-names></name><name><surname>Zareba</surname><given-names>W</given-names></name><name><surname>Klein</surname><given-names>HU</given-names></name></person-group>
<article-title>Impact of the right ventricular lead position on clinical outcome and on the incidence of ventricular tachyarrhythmias in patients with CRT-D</article-title>. <source>Heart Rhythm</source><year>2013</year>;<volume>10</volume>:<fpage>1770</fpage>&#x02013;<lpage>1777</lpage>.<pub-id pub-id-type="pmid">23973954</pub-id></mixed-citation></ref><ref id="EHV422C31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Merchant</surname><given-names>FM</given-names></name><name><surname>Heist</surname><given-names>EK</given-names></name><name><surname>Nandigam</surname><given-names>KV</given-names></name><name><surname>Mulligan</surname><given-names>LJ</given-names></name><name><surname>Blendea</surname><given-names>D</given-names></name><name><surname>Riedl</surname><given-names>L</given-names></name><name><surname>McCarty</surname><given-names>D</given-names></name><name><surname>Orencole</surname><given-names>M</given-names></name><name><surname>Picard</surname><given-names>MH</given-names></name><name><surname>Ruskin</surname><given-names>JN</given-names></name><name><surname>Singh</surname><given-names>JP</given-names></name></person-group>
<article-title>Interlead distance and left ventricular lead electrical delay predict reverse remodeling during cardiac resynchronization therapy</article-title>. <source>Pacing Clin Electrophysiol</source><year>2010</year>;<volume>33</volume>:<fpage>575</fpage>&#x02013;<lpage>582</lpage>.<pub-id pub-id-type="pmid">20070543</pub-id></mixed-citation></ref><ref id="EHV422C32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miranda</surname><given-names>RI</given-names></name><name><surname>Nault</surname><given-names>M</given-names></name><name><surname>Johri</surname><given-names>A</given-names></name><name><surname>Simpson</surname><given-names>CS</given-names></name><name><surname>Michael</surname><given-names>KA</given-names></name><name><surname>Abdollah</surname><given-names>H</given-names></name><name><surname>Baranchuk</surname><given-names>A</given-names></name><name><surname>Redfearn</surname><given-names>DP</given-names></name></person-group>
<article-title>Maximal electric separation-guided placement of right ventricular lead improves responders in cardiac resynchronization defibrillator therapy</article-title>. <source>Clinical Perspective Circ Arrhythm Electrophysiol</source><year>2012</year>;<volume>5</volume>:<fpage>927</fpage>&#x02013;<lpage>932</lpage>.</mixed-citation></ref></ref-list></back></article>